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ABSTRACT 
 




This dissertation summarizes the development of experimental and analytical tools for single cell 
RNA sequencing (scRNA-Seq), including 1) scPLATE-Seq, a FACS- and plate-based scRNA-
Seq platform, which is accurate, robust, fully automated and cost-efficient; 2) metaVIPER, an 
algorithm for transcriptional regulator activity inference based on scRNA-Seq profiles; and 3) 
iterClust, a statistical framework for iterative clustering analysis, especially suitable for dissecting 
hierarchy of heterogeneity among single cells. Further this dissertation summarizes biological 
questions answered by combining these tools, including 1) understanding inter- and intra-tumor 
heterogeneity of human glioblastoma; 2) elucidating regulators of β-cell de-differentiation in 
type-2 diabetes; and 3) developing novel therapeutics targeting cell-state regulators of breast 
cancer stem cells. 
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The “scientific question” that drives the development of the single cell RNA sequencing 
(scRNA-Seq) technique is the need to understand biological states at individual cells level, 
including 1) cell types, e.g. types of neurons in mouse retina [Macosco, 2015], 2) cell cycle 
stages, e.g. G1, S, G2/M stages of mouse embryonic stem cells [Liu, 2017], and 3) 
developmental lineage, e.g. myoblast-to-muscle developmental process [Trapnell, 2014]. 
For the technique per se, scRNA-Seq is supported by two major breakthroughs: 1) the ability of 
doing reverse transcription from tiny amount of mRNA, and 2) the ability of capturing single 
cells in a high-throughput manner. The first successful single cell reverse transcription protocol 
was developed by [Tang, 2009], where poly-A primers are used to capture mRNA. After 1st 
strand synthesis, the primers are removed, and then a poly-A sequence is aligned to the end of 
newly synthesized cDNA. Then a poly-T primer is used for the 2nd strand synthesis to get cDNA 
products. However, this protocol includes 1) multi-steps, and 2) primer cleanup, making it 
inconvenient to perform. The SMART-Seq technique [Ramsköld, 2011] simplified the protocol 
by using “template switching” technique. In SMART-Seq protocol, a specific reverse 
transcriptase is used, which can align a short sequence, know as template switching oligo, 
directly after the 1st strand synthesis. This template switching oligo can be used as handle for 
2nd strand synthesis. Therefore we can add poly-A primer and template switching oligo together 
in the reaction system, greatly simplified the whole process. Since the starting mRNA is tiny, we 
need to do way more rounds of PCR compared to bulk sequencing to get a desirable sequencing 
library. So the next problem they community was facing is PCR bias, which means different 
genes might have different PCR amplification rate, thus greatly confounds the evaluation of gene 
expression. So [Islam, 2013] introduced unique molecular identifier (UMI), which barcodes 
	 3	
individual mRNA transcript. In the final sequencing result, reads with same UMIs will be 
collapsed as 1 transcript, therefore more accurate. 
The major challenge for the single cell capturing platform is throughput. Dated back to 2009 
original protocol [Tang, 2009], single cells were hand-picked. The later FACS- microfluidic- and 
microfluidics-based platforms greatly increase the throughput. For instance, FACS-based 
platforms are compatible with 96 or 384-well plates. Cell suspension is loaded on the FACS 
machine, which will sort single cells into plates according to the florescent labeling of cells. 
Most recent microfluidics-based Fluidigm C1 systems can deal with 800 cells/chip. Cell 
suspension is flowed through microfluidic channels, during which single cells can be captured by 
individual capture site alongside the channel. The microdroplets-based 10x Genomics Chromium 
can deal with thousands cells/run. Cell suspension is flowed through microfluidic channels, 
inside which single cells will be encapsulated by oil droplets, together with magnetic beads 
coated with sequencing primers as well as reaction buffer. 
In this thesis, I will describe the development two analytical tools, metaVIPER and iterClust, for 
better understand biological states using scRNA-Seq data. Also, I will describe the development 
scRNA-Seq platform, scPLATE-Seq. Combing these tools, I will answer three specific 
biological questions, including 1) understanding inter- and intra-tumor heterogeneity of human 
glioblastoma, 2) elucidating regulators of β-cell de-differentiation in type-2 diabetes, and 3) 






scPLATE-Seq for Simple, Automated Single-




Since 2012, multiple scRNA-Seq technologies have been introduced [Kolodziejczyk, 2015]. 
Most involve significant startup cost, an expert operator, or expensive library preparation. Dr. 
Jeremy Worley and I developed a plate-based library prep that incorporates pre-amplification 
pooling, unique molecular identifiers (UMIs) [Islam, 2014], and mRNA enrichment using silanol 
coated magnetic beads. The method uses readily available equipment and is easy to automate. In 
addition, the method has been optimized to reduce barcode cross contamination that can occur in 
pooled pre-amplification reactions. This method allows for plate-based 3’ scRNA-seq with UMIs 
at relatively low cost (~5$/cell), using standard lab equipment. 
2.2 Methods 
2.2.1 scPLATE-Seq protocol 




2.2.2 Expression quantification of HEK293 and U87 single cells. 
After demultiplexing, UMIs from the barcode read (8nt) were concatenated onto the 5’ part of 
corresponding mappable reads using a custom Python script (demultiplex.py). Then the 
concatenated mappable reads were aligned and mapped to UCSC hg38 genome using the STAR 
2.5.1a [Dobin, 2013] with option --quantMode TranscriptomeSAM so that output alignments are 
translated into transcript coordinates for downstream analysis, and --clip5pNbases 8 so that the 
UMI sequences are not mapped. All other options for STAR are set as default. Then the mapped 
transcripts per gene and mapped reads per gene were quantified using a custom Python script 
Figure 2.1 Overview of scPLATE-Seq 
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(CountUMI.py). When measuring mapped transcripts per gene using hamming distance 
threshold 1, only if the hamming distance between two UMIs is greater than 1, then they are 
considered from different transcripts. 
2.2.3 Expression quantification of HEK293 bulk sample. 
The general procedures are the same as described in 2.2.2, besides only the mapped reads per 
gene was considered since UMIs were not included in bulk samples. Since the bulk library is 
also 3’ biased (same chemistry with scPLATE-Seq), log2(RPM+1) was used when measuring 
the correlation between the ensemble single cell and the bulk transcriptome. 
2.2.4 Expression quantification of the mix species experiments. 
The general procedures are the same as described in 2.2.2, besides the concatenated mappable 
reads were aligned and mapped to concatenated UCSC hg38 and mm10 genome with option --
outFilterMultimapNmax 1 so that only reads that uniquely mapped are considered. When 
measuring transcripts per gene I used hamming distance threshold 1. 
2.2.5 Data and software availability 
See Appendix B for detail. 
2.3 Results 
2.3.1 Measuring robustness of scPLATE-Seq 
For robust scRNA-Seq platforms, pooled single cell transcriptomic profiles of relatively 
homogenous cell lines should recapitulate the corresponding bulk transcriptomic profiles [Wu, 
2014]. Therefore we measured the correlation between the ensemble single cell and the bulk 
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transcriptome were measured. The ensemble single cell was created by computationally pooling 
all the raw reads from single cell transcriptomes generated using scPLATE-Seq. Results showed 
bulk transcriptomic profile of HES293 cell line was recapitulated by pooling the corresponding 
single cells, indicating scPLATE-Seq to be a robust scRNA-Seq platform (Figure 2.2). 
 
 
2.3.2 Measuring non-singlet rate and sample barcode cross-talk rate of scPLATE-Seq 
Figure 2.2 Measuring robustness of scPLATE-Seq. For each gene, the log2(RPM+1) 
values from the ensemble and bulk were plotted against each other. 
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Mixture of human (U87) and mouse (3T3) cells were analyzed by scPLATE-Seq. Comparable 
human and mouse mapped reads/transcripts among all samples is caused by sample barcode 
cross-talk, while that among few samples is caused by non-singlet. Results showed non-singlet 
events are rare, while in general sample barcode cross-talk events are significantly reduced by 
reducing rounds of Nextera PCR and purifying SMRT PCR products using SPRI or silanol 
coated magnetic beads. Sample barcode cross-talk usually happens during Nextera PCR 
amplification, when SMRT PCR products from each individual well are pooled. Excessive free-
floating RT (Reverse Transcription) primers, which contain sample-barcode, can be attached to 
SMRT PCR products from different wells during Nextera PCR amplification, causing cross-
contamination between wells. SMRT PCR products purification will remove free-floating RT 
primers, therefore significantly reduce sample barcode cross-talk events (SMRT PCR, initial 
amplification of RT products within each well; Nextera PCR, final amplification and adding 
Illumina primers after SMRT PCR products are pooled). Noticeably, sample barcode cross-talk 
events are more visible when using UMI to quantify transcriptomic profiles, compared to using 
mapped reads. This is because transcriptomic profile quantification using UMI is more sensitive, 
while cross-talk events happen at later PCR cycles will not significantly influence percentage of 





2.3.3 Measuring effectiveness of hamming correction 
UMIs were introduced to reduce PCR amplification rate bias in scRNA-Seq. During reverse 
transcription (RT), each individual transcript will be labeled with a unique UMI sequence. When 
quantifying transcriptomic profiles, sequencing reads mapped to the same gene with same UMI 
sequence will be collapsed and considered as from the same transcript. Hamming distance 
correction is used to correct PCR or sequencing errors on UMI sequences (Figure 2.4). 
Figure 2.3 Measuring non-singlet rate and sample barcode cross-talk rate of scPLATE-
Seq. Percentage of reads (A-D) and transcripts (E-H) uniquely mapped to human/mouse 
under 15 cycles SMRT, 12 cycles Nextera, SPRI cleanup (A and E), 15 cycles SMRT, 8 
cycles Nextera, SPRI cleanup (B and F), 12 cycles SMRT, 12 cycles Nextera, SPRI cleanup 
(C and G) and 12 cycles SMRT, 12 cycles Nextera, Silane cleanup (D and H) were 





2.3.4 Measuring sensitivity and technical noise level of scPLATE-Seq 
As measure of sensitivity, I checked the distribution of number of mapped reads, mapped 
transcripts and detected genes per cell. As measure of technical noise level, I checked average 
expression and corresponding CV for each gene (Figure 2.5). 
Figure 2.4 Measuring effectiveness of hamming correction. (A, D) Comparison between 
mapped reads and detected transcripts without hamming correction. (B, E) Comparison 
between mapped reads and detected transcripts with hamming correction (distance 1). (C, F) 






2.3.5 Measuring biological differences over batch effect of scPLATE-Seq 
Results showed different cell lines (HEK293 and U87) were separated on 2D tSNE plot [Maaten, 
2008]. Slight batch effect was observed, that HEK293 cells profiled in the same plate tend to 
cluster together. However such slight batch effect is not influencing the interpretation of biology 
(Figure 2.6). 
Figure 2.5 Measuring sensitivity and technical noise level of scPLATE-Seq. (A-C and F-
H) Sensitivity: distribution of number of mapped reads, mapped transcripts and detected 
genes (mapped reads/transcripts >0) of HEK293 and U87 cells. (D, E, I and J) Technical 
noise level: average expression measured by log2(RPM+1) or log2(TPM+1) and 





Figure 2.6 Measuring biological differences over batch effect of scPLATE-Seq. (A and 
B) tSNE [Maaten, 2008] plot based on log2(RPM+1) (A) and log2(TPM+1) measurements 






Quantitative Assessment of Protein Activity in 
Orphan Tissues and Single Cells Using the 
metaVIPER Algorithm [Ding, 2018a]
	 15	
3.1 Introduction 
Most biological events are characterized by the transition between two cellular states 
representing either two stable physiologic conditions, such as during lineage specification 
[Clevers, 2006; Thiery, 2009] or a physiological and a pathological one, such as during 
tumorigenesis [Hanahan & Weinberg, 2011; Thiery, 2002]. In either case, cell state transitions 
are initiated by a coordinated change in the activity of key regulatory proteins, typically 
organized into highly interconnected and auto-regulated modules, which are ultimately 
responsible for the maintenance of a stable endpoint state. Dr. Califano have used the term 
“master regulator” (MR) to refer to the specific proteins, whose concerted activity is necessary 
and sufficient to implement a given cell state transition [Califano & Alvarez, 2017].  Critically, 
individual MR proteins can be systematically elucidated by computational analysis of regulatory 
models (interactomes) using MARINa (Master Regulator Inference algorithm) [Lefebvre, 2010] 
and its most recent implementation supporting individual sample analysis, VIPER (Virtual 
Inference of Protein activity by Enriched Regulon) [Alvarez, 2016]. These algorithms prioritize 
the proteins representing the most direct mechanistic regulators of a cell state transition, by 
assessing the enrichment of their transcriptional targets in genes that are differentially expressed. 
For instance, a protein would be considered significantly activated in a cell-state transition if its 
positively regulated and repressed targets were significantly enriched in overexpressed and 
underexpressed genes, respectively. The opposite would, of course, be the case for an inactivated 
protein. As proposed in [Alvarez, 2016], this enrichment can be effectively quantitated as 
Normalized Enrichment Score (NES) using the Kolmogorov-Smirnov statistics [Subramanian, 
2005]. Dr. Alvarez have shown that the NES can then be effectively used as a proxy for the 
differential activity of a specific protein [Alvarez, 2016]. Critically, such an approach requires 
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accurate and comprehensive assessment of protein transcriptional targets. This can be 
accomplished using reverse-engineering algorithms, such as ARACNe (Accurate Reverse 
Engineering of Cellular Networks) [Basso, 2005] and others (reviewed in [Hecker, 2009]), as 
also discussed in [Basso, 2005]. 
MARINa and VIPER have helped elucidate MR proteins for a variety of tumor related [Aytes, 
2014; Bisikirska, 2016; Carro, 2010; Chen, 2014; Chudnovsky, 2014; Della Gatta, 2012; 
Rodriguez-Barrueco, 2015], neurodegenerative [Aubry, 2015; Brichta, 2015; Ikiz, 2015], stem 
cell [Kushwaha, 2015; Talos, 2017], developmental [Lefebvre, 2010] and neurobehavioral 
[Repunte-Canonigo, 2015] phenotypes that have been experimentally validated. The dependency 
of this algorithm on availability of tissue specific models, however, constitutes a significant 
limitation because use of non-tissue-matched interactomes severely compromises algorithm 
performance [Aytes, 2014]. Since ARACNe requires N ≥ 100 tissue-specific gene expression 
profiles, representing statistically independent samples, some tissue contexts may lack adequate 
data for accurate interactome inference. These "orphan tissues" include, for instance, rare or 
poorly characterized cancers as well as progenitor states during lineage differentiation. In 
addition, the specific tissue lineage of a sample may be poorly defined, thus preventing selection 
of appropriate interactome models. Consider, for instance, a single cell isolated from a 
heterogeneous sample, such as whole brain or stroma-infiltrated tumor, where many highly 
distinct and often uncharacterized cell lineages are inextricably commingled. 
To address this challenge, Dr. Califano, Dr. Alvarez and I reasoned that while regulatory models 
are clearly lineage specific, due to the distinct epigenetic state of the cells, the transcriptional 
targets of a specific protein (i.e., its regulon) may be at least partially conserved across a small 
subset of distinct lineages. Thus, once a sufficient number of tissue specific interactomes is 
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available, the likelihood that one or more of them may represent a good model for the regulon of 
a specific protein increases, even though one may not know a priori which model may represent 
the best match for each protein. Indeed, the regulons of different proteins may be optimally 
represented within different interactomes. This is further helped by the fact that VIPER analysis 
is robust if at least 40% of a protein’s regulon is accurately inferred [Alvarez, 2016]. Conversely, 
as shown in Figure 3.1 when a protein regulon is incorrectly assessed for a specific tissue, it is 
not consistent with the tissue-specific gene expression signature, thus producing no significant 
enrichment. Taken together, these observations constitute the basis for the implementation of a 






Figure 3.1 Highest absolute NES values are obtained from tissue-matched 
interactomes. A) Since tissue-matching regulons are in general best models for proteins in 
that specific tissue, I conclude that correctly assessed regulons usually give high absolute 
activity. This is demonstrated by that across all tissue types, tissue-matching interactome 
harbors the most regulons with highest absolute activity. B) In some particular cases, tissue-
matching regulons may not constitute the best model. For instance, as shown, in breast 
invasive carcinoma (BRCA), proteins in the upper panel are best modeled by regulons from 
other tissues. Also, in some cases, tissue-matching regulons may not be the only appropriate 
model. For instance, besides BRCA regulons, proteins in the lower panel can also be 
appropriately modeled by regulons from other tissue types. 
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MetaVIPER implements a statistical framework for evidence integration across a large repertoire 
of context-specific interactomes, see Methods for details. The algorithm is based on the 
assumption that only regulons that accurately represent the transcriptional targets of specific 
proteins in the tissue of interest will produce statistically significant enrichment in genes that are 

















To assess whether metaVIPER can effectively assess protein activity in context-independent 
fashion I perform a number of distinct benchmarks. First, I assessed whether results produced by 
analysis of context-specific interactomes (e.g., inferred from breast cancer samples) could be 
effectively reproduced when only interactomes from other tissues are used in integrative fashion. 
I also test whether the ability to assess dysregulation of proteins whose encoding gene harbored a 
recurrent somatic alteration was improved by metaVIPER. Finally, I assess the algorithm’s 
ability to transform low-depth single cell RNA-Seq profiles into highly reproducible protein 
activity profiles that accurately reflect cell state, while removing technical artifacts and batch 
Figure 3.2:  Inferring protein activity with metaVIPER. (A) Overview of metaVIPER. 
The set of transcriptional targets for each regulatory protein (its regulon) constitutes the 
fundamental building blocks of an interactome, which reflect its overall, context-specific 
regulatory control structure. MetaVIPER identifies the regulon that best recapitulates the 
regulatory targets of a protein by assessing its enrichment in the tissue specific differential 
expression signature. In the example shown here, for instance, the regulon for protein CUX1 
in an unknown or orphan tissue is better recapitulated by the uterine corpus endometrial 
carcinoma (UCEC)-based regulon, while the transcriptional program for the androgen 
receptor protein (AR) is better recapitulated by the Cervical squamous cell carcinoma and 
endocervical adenocarcinoma (CESC) and glioblastoma (GBM)-based regulons. The 
numbers indicate –log10(p-value) for enrichment of the regulons on the gene expression 
signature, as computed by VIPER. (B) Impact of recurrent coding somatic mutations on 
metaVIPER-inferred protein activity. Fraction of proteins showing significant association 
between metaVIPER-inferred protein activity and somatic mutations (p < 0.01) is presented. 
VIPER analysis was performed using the tissue-matched network (tissueMatch), 
metaVIPER was performed  by integrating the results from individual interactomes using 
maxScore, avgScore and NESScore methods; the baseline control was computed by using 
intercatomes selected at random (randomMatch). The X-axis represents the minimum 
number of TCGA samples presenting the specific gene mutation required for incluion of the 
encoded protein in the analysis. (C) Inference of protein activity for orphan tissues. 
MetaVIPER can effectively reproduce differential protein activity in TCGA tissues, even 
when the corresponding matched interactome is removed from the analysis. The only partial 
exception is represented by for two tissue lineages – liver hepatocellular carcinoma (LIHC) 
and testicular germ cell tumors (TGCT) – which are defined by highly specific regulatory 
programs. The probability density distribution for the correlation between protein activities 
(NES) inferred by metaVIPER using all available interactomes vs. metaVIPER using all but 
the tissue-matched interactome (Pearson’s correlation) across all samples is shown by the 
violin plots. 
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effects, compared to state of the art gene expression based methods. These improvements 
significantly increase the ability to analyze the biological function and relevance of gene 
products whose mRNAs are undetectable in low-depth, single cell RNA-Seq data (dropout 
effect), without any a priori knowledge of the single cell’s lineage. In particular, it allows more 
stringent analysis of critical lineage markers, for which no mRNA reads may be detectable in 
individual cells, either individually or as a set, supporting a “virtual FACS” analysis. 
3.2 Methods 
3.2.1 Regulatory networks 
All regulatory networks were reverse engineered by ARACNe [Basso, 2005] and summarized in 
Table. 3.1. Core TCGA RNA-Seq derived interactomes are available in R-package 
aracne.networks from Bioconductor [Giorgi, 2017]. The TCGA human SKCM network was 
assembled from RNA-Seq profiles. TCGA RNA-Seq level 3 data (counts per gene) was obtained 
from the TCGA data portal, and normalized by Variance Stabilization Transformation (VST), as 
implemented in the DESeq package from Bioconductor [Anders  & Huber, 2010]. The human B 
lymphocyte interactome were reported by [Basso, 2005]. The human T lymphocyte interactome 
were reported by [Piovan, 2013]. The human brain tumor regulatory networks were assembled 
from four more gene expression datasets besides the TCGA glioblastoma RNA-Seq dataset. For 
the Rembrandt, [Phillips, 2006], TCGA-Agilent and TCGA-Affymetrix, informative probe 
clusters were assembled with the cleaner algorithm [Alvarez, 2009] and the expression data was 
summarized and normalized with the MAS5 algorithm as implemented in the affy R-package 
from Bioconductor [Gautier, 2004]. Differences in sample distributions were removed with the 
robust spline normalization procedure implemented in the lumi R-package from Bioconductor 
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[Du, 2008]. In a similar way, differences in sample distribution for the TCGA-Agilent dataset 
were removed by the robust spline normalization method. ARACNe was run with 100 bootstrap 
iterations using 1,813 transcription factors (genes annotated in Gene Ontology molecular 
function database, as GO:0003700, 'transcription factor activity', or as GO:0003677, 'DNA 
binding', and GO:0030528, 'transcription regulator activity', or as GO:00034677 and GO: 
0045449, 'regulation of transcription'), 969 transcriptional cofactors (a manually curated list, not 
overlapping with the transcription factor list, built upon genes annotated as GO:0003712, 
'transcription cofactor activity', or GO:0030528 or GO:0045449) and 3,370 signaling pathway 
related genes (annotated in GO Biological Process database as GO:0007165 'signal transduction' 
and in GO cellular component database as GO:0005622, 'intracellular', or GO:0005886, 'plasma 
membrane'). Parameters were set to 0 DPI (Data Processing Inequality) tolerance and MI 
(Mutual Information) p-value (using MI computed by permuting the original dataset as null 
model) threshold of 10-8. 
  
	 22	
Table 3.1 Interactomes used in this work and datasets used to reverse engineer them. 
Tissue Type Expression source Acronym # Samples # Regulators # Targets # Interactions 
Bladder urothelial carcinoma TCGA RNA-Seq BLCA 427 6054 19785 489101 
Breast invasive carcinoma TCGA RNA-Seq BRCA 1212 6054 19359 331919 
Cervical squamous cell carcinoma and 
endocervical adenocarcinoma 
TCGA RNA-Seq CESC 309 6056 19839 583961 
Colon adenocarcinoma TCGA RNA-Seq COAD 500 6056 19820 413789 
Esophageal carcinoma TCGA RNA-Seq ESCA 198 5961 18679 529286 
Glioblastoma multiforme TCGA RNA-Seq GBM 166 6056 19858 563850 
Head and neck squamous cell 
carcinoma 
TCGA RNA-Seq HNSC 566 6055 19772 423104 
Kidney renal clear cell carcinoma TCGA RNA-Seq KIRC 606 6054 19843 350478 
Kidney renal papillary cell carcinoma TCGA RNA-Seq KIRP 323 6055 19858 452653 
Acute myeloid leukemia TCGA RNA-Seq LAML 179 6007 19269 531535 
Liver hepatocellular carcinoma TCGA RNA-Seq LIHC 423 6056 19829 469922 
Lung adenocarcinoma TCGA RNA-Seq LUAD 576 6055 19742 399513 
Lung squamous cell carcinoma TCGA RNA-Seq LUSC 552 6054 19741 455032 
Ovarian serous cystadenocarcinoma TCGA RNA-Seq OV 299 6007 19140 647358 
Pheochromocytoma and 
paraganglioma 
TCGA RNA-Seq PCPG 187 6506 19861 603617 
Prostate adenocarcinoma TCGA RNA-Seq PRAD 550 6053 19820 330922 
Rectum adenocarcinoma TCGA RNA-Seq READ 177 6056 19856 557911 
Sarcoma TCGA RNA-Seq SARC 265 6112 20479 526591 
Skin cutaneous melanoma TCGA RNA-Seq SKCM 472 6053 19840 425361 
Stomach adenocarcinoma TCGA RNA-Seq STAD 307 6056 21663 561858 
Testicular germ cell tumors TCGA RNA-Seq TGCT 156 6056 19860 432621 
Thyroid carcinoma TCGA RNA-Seq THCA 568 6053 19861 317582 
Thymoma TCGA RNA-Seq THYM 122 6056 19862 387923 
Uterine corpus endometrial carcinoma TCGA RNA-Seq UCEC 581 6055 19716 469845 
T lymphocyte [Della Gatta, 2012] T 233 5086 13834 324963 
B lymphocyte [Lefebvre, 2010] B 201 3651 8699 207336 
Skin cutaneous melanoma TCGA RNA-Seq SKCM 472 6201 19840 432922 
Glioblastoma multiforme REMBRANDT NA 804 3921 12683 482879 
Glioblastoma multiforme [Phillips, 2006] NA 176 3099 8964 382144 
Glioblastoma multiforme TCGA affymetrix NA 202 3433 9812 421108 
Glioblastoma multiforme TCGA agilent NA 202 5560 17355 988514 
 
2.2.2 Association somatic mutations with metaVIPER inference 
I consider somatic mutations that happen in the same amino acid of a protein within at least 3 
patients as recurrent somatic mutations. Then for each protein, I did enrichment analysis with 
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activity profile for each patient as signature, and patient harboring recurrent somatic mutation for 
that specific protein as enriching set. I consider proteins with significant enrichment score (p < 
0.01) as showing significant association between inferred protein activity and recurrent somatic 
mutations. Then I check the fraction of proteins that can be associated with recurrent somatic 
mutations, and use that as criteria in evaluating the performance between VIPER and 
metaVIPER. In order to get enough mutated patient for each protein, this analysis is done in a 
tumor type non-specific manner. 
3.2.3 Preparation of glioblastoma mouse model 
PDGFB-IRES- CRE expressing retrovirus was injected into the rostral subcortical white matter 
of adult Pten lox/lox /p53 lox/lox /luciferase- stop-lox transgenic mice [Lei, 2011; Sonabend, 2013]. 
Mice developed brain tumors with the histopathological features of glioblastoma by 28 days post 
injection with retrovirus. 
3.2.4 Generate scRNA-Seq profiles for glioblastoma mouse model 
In Dr. Canoll’s lab, following IACUC guidelines, animals were sacrificed at the first sign of 
morbidity. Ex-vivo gross total resection of the tumor was performed and tumor cells were 
isolated using enzymatic digestion [Gensert, 2001]. The isolated cells were cultured in a 2:1 ratio 
of basal media (DMEM, N2, T3, 0.5% FBS, and penicillin/streptomycin/amphotericin) in B104 
conditioned media [Canoll, 1996]. This media was further supplemented with PDGF-AA 
(Sigma-Aldrich; St. Louis, MO) and FGFb (Gibco; Grand Island, NY) to a concentration of 
10ng/ml. Dr. Sims’ lab loaded dissociated cells into a Fluidigm Integrated Fluidic Circuit with 
capture sites designed for 10-17 µm diameter cells after staining the single cell suspension with 
Calcein AM (Life Technologies). They then imaged the cells that had been captured on-chip 
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with both bright field and fluorescence microscopy using an inverted Nikon Eclipse Ti-U 
epifluorescence microscope with a 20x, 0.75 NA air objective (Plan Apo λ, Nikon), a 473 nm 
diode laser (Dragon Lasers), and an electron multiplying charge coupled device (EMCCD) 
camera (iXON3, Andor Technologies). This allowed them to identify capture sites with zero, one, 
and more than one cell and also to identify capture sites containing living cells, based on the 
Calcein AM fluorescence. They then lysed the cells, reverse transcribed mRNA into cDNA, and 
pre-amplified full-length cDNA by PCR automatically using the Fluidigm C1 Autoprep 
instrument according to the manufacturer’s instructions. Finally, they harvested individual cDNA 
libraries from the microfluidic device and converted them into indexed, Illumina sequencing 
libraries by in vitro transposition and PCR using the Nextera system (Illumina). The pooled 
libraries were sequenced on a single lane of an Illumina HiSeq 2000 with single-end 100-bp 
reads. After demultiplexing, the resulting raw reads were aligned to the murine genome and 
transcriptome annotation (mm10, UCSC annotation from Illumina iGenomes) with Tophat 2. 
Uniquely aligned, exonic reads were then quantified for each gene using HTSeq. In total they 
obtained 85 single cells. 
3.2.5 Data and software availability 
See Appendix C for detail. 
3.3 Results 
3.3.1 Overview of metaVIPER 
Let’s assume a tissue context T for which a matched tissue specific interactome were not 
available. Furthermore, without loss of generality, let’s focus on a specific protein of interest P 
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and on its T-specific regulon RT. Given a sufficient number of additional tissues T1 … TN for 
which accurate, context-specific interactomes are available, I hypothesize that RT will be at least 
partially recapitulated in one or more of them. Based on previous results7, VIPER can accurately 
infer differential protein activity, as long as 40% or more of its transcriptional targets are 
correctly identified. As a result, even partial regulon overlap may suffice. Indeed, paradoxically, 
there are cases where a protein’s regulon may be more accurately represented in a non-tissue 
matched interactome than in the tissue-specific one. This may occur, for instance, when 
expression of the gene encoding for the protein of interest has little variability in the tissue of 
interest and greater variability in a distinct tissue context where the targets are relatively well 
conserved. A key challenge, however, is that one does not know a priori which of the tissue-
specific interactomes may provide reasonable vs. poor models for RT.  
To address this challenge, I leverage previous studies showing that if an interactome-specific 
regulon provides poor RT representation, approaching random selection in the limit, then it will 
also not be statistically significantly enriched in genes that are differentially expressed in a 
tissue-specific signature ST. Thus, if one were to compute the enrichment of all available 
regulons for the protein P in the signature ST, only those providing a good representation will 
produce statistically significant enrichment, if P is differentially active in the tissue of interest. 
Conversely, if the protein is not differentially active in T, then no regulon RT1 … RTN should 
produce statistically significant enrichment.  If these assumptions were correct, given a sufficient 
number of tissue-specific interactomes, this would provide an efficient way to integrate across 
them to compute the differential activity of arbitrary proteins in tissue contexts for which a 
suitable interactome model may be missing. 
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To determine the best strategy for integrating the statistics of the enrichment across multiple 
interactomes, I compared several approaches. Specifically, for each protein, I first computed 
enrichment using a tissue-matched interactome (tissueMatch). This corresponds to the original 
implementation of the VIPER algorithm. I then compared these results to those obtained using 
different metrics to integrate across the regulons of all non-tissue-matched interactomes, 
including: (a) the NES with the most statistically significant absolute value (maxScore); (b) the 
average of all NES scores (avgScore) and (c) the weighted-average of all NES scores, weighed 
by the NES absolute value (NESScore). For these tests, I used a total of 24 interactomes 
generated from TCGA cohorts, see Table 3.1 [Giorgi, 2017].  
To objectively evaluate the performance of these alternative integrative methods, I considered a 
comprehensive set of proteins, whose genes harbor recurrent somatic mutations, as reported by 
both TCGA and COSMIC (see Methods). These mutations drive tumorigenesis by altering the 
activity of key oncogenes and tumor suppressors and have been used to identify proteins for 
targeted inhibitors, based on the oncogene additional paradigm [Weinstein, 2002]. I thus assessed 
method performance by assessing the statistical significance of the correlation between 
metaVIPER-inferred protein activity and the presence of a recurrent genetic alterations in the 
corresponding gene locus (p < 0.01), under the assumption that better methods would yield 
higher significance. To produce an optimal metric across all recurrent mutational events, I 
assessed correlation as a function of recurrence (Figure 3.2B). Indeed, the more recurrent a 
mutation is, the more likely it is to be functionally relevant and thus affect the corresponding 
protein’s activity. Recurrence is reported as the number of samples in TCGA and COSMIC 
where a specific gene locus was mutated, see Methods. As shown in Figure 3.2B, there is a clear 
trend showing that the more recurrently mutated a gene locus is, the larger the fraction of 
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proteins showing statistically significant correlation between metaVIPER-inferred protein 
activity and mutational state. For instance, about 50% of the genes harboring locus-specific 
mutations in at least 30 TCGA samples could be detected as producing differentially active 
proteins by metaVIPER analysis (p < 0.01). 
Surprisingly, based on this metric, all four strategies for cross-tissue integration (metaVIPER) 
significantly outperformed the use of tissue-specific interactomes, i.e. the original VIPER 
algorithm (tissueMatch). This suggests that integrating the structure of regulatory networks 
across a large number of representative tissue types provides a more informative regulon 
representation on an individual protein basis. The randomMatch method serves as a baseline 
negative control, in which for each sample, protein activity was computed using VIPER with an 
interactome selected at random. As discussed in the following sections, I performed several 
additional benchmarks to comprehensively and systematically assess the method’s performance 
in orphan tissues, as well in single cells. 
3.3.2 MetaVIPER-based protein activity inference in orphan tissues  
Small sample size severely undermines the performance of ARACNe, which typically requires at 
least 100 independent samples, representative of the same tissue lineage [Margolin, 2006] to 
perform accurate regulon inference for VIPER analysis. This significantly limits the ability to 
accurately measure protein activity in orphan tissues, defined as rare or poorly characterized 
tissue types, for which the number of available gene expression profiles is not sufficient to 
produce an accurate interactome model. For instance, considering tumor cohorts in the TCGA 
repository, I identified Cholangiocarcinoma (N = 36) and Uterine Carcinosarcoma (N = 57) 
could be considered orphan tissues for which an accurate ARACNe network could not be 
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generated. Orphan tissues also include a variety of normal or non-cancer, disease-related cell 
states that lack appropriate gene expression profile characterization, including many of the 
intermediate states of differentiation representing multipotent or progenitor population. 
Since metaVIPER is designed to infer protein activity without requiring a tissue-specific 
regulatory model, I designed an objective benchmark to assess metaVIPER’s ability to 
accurately measure protein activity in orphan tissues. I first assembled a gold-standard set using 
metaVIPER to assess the activity of all proteins for which an ARACNe regulon was generated 
(see Methods), in each sample of each TCGA cohort, using all available TCGA interactomes 
including the tissue-matched one. This is preferred to using only the tissue-matched interactome 
because from the objective benchmark using mutational data this methodology has emerged as 
being more accurate than the original VIPER analysis. However, for completeness, I also report 
results of this analysis using the tissue-matched interactomes as gold-standard, see Figure 3.3. I 
then performed the same analysis using metaVIPER with all available TCGA interactomes, 
except for the tissue-matched one. For instance, consider Rectum Adenocarcinoma (READ) as a 
tumor for which an ARACNe interactome could not be accurately inferred. I would then 
compute the VIPER-inferred activity of all proteins in each TCGA READ sample using either all 
available TCGA interactomes (gold-standard reference) or all interactomes except for the READ 
interactome, exactly as if it were not available. I then measure overall protein activity correlation 
between the two analyses as a quality metric for metaVIPER ability to correctly infer protein 
activity in the absence of a tissue-matched interactome.  This benchmark was performed for each 
of the all 24 tissue types in TCGA, see Table 3.1 [Giorgi, 2017]. Results show extremely strong 
average correlation (ρ > 0.97) between the two analyses for 22 out of 24 tissues (excluding LIHC 
and TGCT). This suggests that, even in the absence of a tissue-matched model, most tissues may 
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be studied virtually without loss of resolution using metaVIPER (Figure 3.2C, Figure 3.3). Thus 
most orphan tissues can be studied using metaVIPER with virtually no notable result quality 
degradation. Not surprisingly, the two outlier tissues have a rather unique nature. Indeed, liver 
hepatocellular carcinoma (LIHC) is originated from hepatocytes, which are unique endoderm 
derived secretory cells [Thorgeirsson, 2002]. Similarly, testicular germ cell tumors (TGCT) 
originate from testicular germ cells, which are specialized pluripotent cells that give rise to 
gametes [Bosl & Motzer, 1997]. Hepatocytes and testicular germ cells are thus highly 
specialized issues with no other related tissues among the 24 in TCGA. However, as the number 
of interactomes in my repertoire grows the probability of having true outlier tissues will decrease. 
Note, however that, despite their specialized nature even the two outlier tissues presented high 







This raises the important issue of an objective metric to assess whether metaVIPER – when used 
with a specific repertoire of tissue specific interactomes – is adequate for inferring protein 
activity in tissues lacking a matched interactome (i.e., orphan tissues). To achieve this goal, as 
proposed in [Basso, 2005], I will use the Empirical Cumulative Distribution Function of the 
absolute value of the VIPER Normalized Enrichment Score (ECDF|NES|) of all proteins in an 
orphan tissue sample or samples [Aytes, 2014]. In Figure 3.4, I show violin plots for the 
ECDF|NES| of each TCGA cohort, using the corresponding tissue-matched interactome. The 
Figure 3.3 Inference protein activity for orphan tissues. Correlation of protein activity 
inferred from 1) metaVIPER, with all available interactomes (all), 2) metaVIPER, with all 
non-matching interactomes (non) and 3) VIPER with matching interactome (mch). Then 
violin plots show the probability density distribution for the Pearson’s correlation coefficient 
for each of the evaluated tissue types. 
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rightmost plot (TCGA) shows the average of all cohort-specific probability densities. This 
provides a useful reference to assess whether a specific interactome repertoire is adequate for the 
metaVIPER-based analysis of an orphan tissue. For instance, I analyzed LAML samples using 
only a GBM interactome, which would be clearly inappropriate since LAML and GBM cells 
belong to epigenetically distinct lineages. The result is shown in the first-to-last violin plot 
(Neg.Ctrl.). As shown this ECDF is clearly an outlier with respect to All-TCGA. Thus, by 
comparing the ECDF for a tissue of interest against the All TCGA reference, one can effectively 






3.3.3 Single cell analysis  
The last few years have seen tremendous development of single-cell profiling methodologies and 
in particular of single cell RNA-Seq (scRNA-Seq). The advent of these technologies provides 
Figure 3.4 Quality control for protein activity analysis.  Since properly assigned regulons 
give high absolute normalized enrichment score (Figure 3.1), therefore I use the Empirical 
Cumulative Distribution Function of the absolute value of the VIPER Normalized 
Enrichment Score (ECDF|NES|) of all proteins with significant predicted activity to estimate 
whether the protein activity analysis is satisfactory. I provided the distribution of the 
proposed score within each tumor type (GBM, OV etc.) as well as among all TCGA samples 
(TCGA) using tissue-matching interactome as references for trustworthy protein activity 
analysis. I also analyzed LAML samples with GBM interactome, which is completely 
misassigned (LAML and GBM have distinct lineage origination) as the negative control 
(Neg.Ctrl.). If metaVIPER analysis gives similar result, probably the included interactomes 
don’t have a satisfactory coverage on regulatory information of the analyzed samples. 
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new insight in understanding transition, maintenance, and cell-cell communication processes, 
across cell states and at an individual cell resolution [Kolodziejczyk, 2015]. However, a major 
challenge of these approaches is related to the very low depth of sequencing ranging between 
10K and 200K reads per cell. While this is sufficient to perform coarse analyses, such as multi-
dimensional clustering to identify molecularly distinct sub-populations, it is extremely 
ineffective in precisely quantitating the expression of individual genes. Indeed, the vast majority 
of genes lack even one mRNA read in individual cells (dropouts) and a large number have a 
single read. Due to these significant dropout effects, elucidating biological mechanisms at the 
single cell level remains challenging. In contrast, as shown in [Alvarez, 2016], VIPER analysis is 
largely unaffected by sequencing depth because differential protein activity is assessed based on 
the differential expression of hundreds of transcriptional targets. Thus, measurement and 
biological noise sources are effectively averaged out, resulting in highly reproducible 
measurements. Indeed, I have shown that VIPER-inferred protein activity profiles from FFPE 
samples were extremely well correlated to those from fresh-frozen samples, despite dramatic loss 
of correlation at the gene expression level [Alvarez, 2016], leading to NYS CLIA approval of 
two VIPER-based tests. As a result, one would expect VIPER to be well suited to performing 
analysis of single cell populations in a way that is amenable to quantitative protein activity 
assessment. 
Unfortunately, however, when dealing with heterogeneous samples, the specific tissue context of 
each individual cell cannot be determined a priori. Even if this were possible, it is unlikely that 
context specific interactomes would be available for rare lineages and progenitor states that are 
captured by single cell profiling methodologies. MetaVIPER represents a useful alternative in 
these cases, because, while preserving the robustness of VIPER, it is agnostic to tissue type and 
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should thus be well-suited to analysis of single cell gene expression profiles from heterogeneous 
tissues. 
To illustrate metaVIPER applicability to single cell expression profile data, Drs. Canoll and Sims 
groups specifically profiled 85 single cells (see Methods) from a mouse glioblastoma (GBM) 
model [Lei, 2011; Sonabend, 2013]. Previous studies have demonstrated that GBM comprises 
two major subtypes, mesenchymal (MES) and Proneural (PN), which may present different 
proliferation capability (Prolif) [Carro, 2010; Phillips, 2006; Verhaak, 2010; Ceccarelli, 2016]. I 
inferred protein activity at the single cell level by metaVIPER analysis across 5 brain tumor 
interactomes, and 24 TCGA human cancer tissue interactomes (see Methods and Table 3.1). 
Contrary to gene expression profile analysis, the inferred protein activity signatures clearly 
captured single cells representing MES and PN subtypes. Indeed, unsupervised metaVIPER 
analysis recapitulated previously reported subtype-specific master regulator proteins [Carro, 
2010], which were identified among the most dysregulated on a single-cell basis (Figure 3.5A). 
Such level of resolution could not be recapitulated by differential gene expression analysis, 
largely due to transcript-level noise in individual cells (Figure 3.5B). Unsupervised clustering 
analysis of metaVIPER-inferred protein activity efficiently separated single cells in two major 
groups, with ~40% of the cells recapitulating the activity pattern of previously described MR 
proteins of MES (FOSL1, FOSL2, RUNX1, CEBPB, CEBPD, MYCN, ELF4), and the remaining 
~60% recapitulating those of the PN such as OLIG2 and ZNF217. In sharp contrast, 
unsupervised, gene-expression based cluster analysis could not effectively separate individual 
cells in distinct clusters (Figure 3.5A, B). Indeed, ~40% of the critical subtype-related proteins 
were undetectable at the gene expression level in any of the single cells (black horizontal bars in 
Figure 3.5A). Expression profiles from single cells are very noisy, due to low sequencing depth, 
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thus reducing the ability to study their biology. Indeed, low depth of sequencing represents a 






Quality of single cell gene expression profiles is generally reflected by the number of detected 
genes [Kolodziejczyk, 2015]. Higher quality gene expression profiles, as identified by higher 
transcriptome complexity, tend to result in higher correlation between the profiles of single cells 
in the same sub-population clusters (Figure 3.6A, B). Once processed with metaVIPER, however, 
not only intra-population correlation between individual cells increases significantly but it also 
becomes virtually independent of transcriptome complexity (Figure 3.6C). This is because 
Figure 3.5 Inference of protein activity for single cells from GBM mouse model.  (A) 
MetaVIPER-based protein activity analysis of single cells from a mouse GBM model [Lei, 
2011; Sonabend, 2013] by unsupervised clustering using all annotated transcriptional 
factors, co-transcriptional factors and signaling proteins. Two major clusters were identified, 
corresponding to established Mesenchymal (MES, blue) and Proneural (PN, turquoise) 
subtypes, with varying proliferative (Prolif) potential. Indeed, among the top 200 
transcriptional factors (i.e., with the highest inter-cluster activity variability), I found 
established master regulatory transcriptional factors of the MES (FOSL1, FOSL2, RUNX1, 
CEBPB, CEBPD, MYCN, ELF4), PN (OLIG2, ZNF217) and Prolif (HMGB2, SMAD4, 
PTTG1, E2F1, E2F8, FOXM1) subtypes [Carro, 2010]. (B) Subtype representation is lost 
when clustering is performed based on gene expression profiles. 
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protein activity inference is based on the expression of many target genes and is thus much more 






I further tested my methodology on single cell data from tissue representing a complex mixture 
of melanoma cells and infiltrating B and T lymphocytes [Tirosh, 2016]. By integrating 
interactomes representative of skin cutaneous melanoma (SKCM, see Methods), B [Basso, 2005] 
and T [Piovan, 2013] lymphocytes, as well as 24 TCGA human cancer tissue [Giorgi, 2017] 
(Table 3.1), metaVIPER was able to infer protein activity profiles that effectively discriminate 
between these different cell types (Figure 3.7A). Furthermore, it revealed differential activity of 
established lineage markers that could not be detected at the gene expression level (Figure 3.7B-
J). This represents a critical value of this approach, as many important lineage markers and other 
transcriptional regulators may yield no scRNA-Seq reads, due to their relatively low transcript 
Figure 3.6 Single cell quality as confounding factor in understanding heterogeneity and 
regulatory properties. With expression measured by both log2(rpm+1) (A) and variance 
stabilizing transformation (VST) in DESeq R package [Anders  & Huber, 2010] (B), cells 
with higher quality (higher number of genes detected) tend to have higher correlation with 
other cells. In some cases, inter-population correlation between high quality cells even 
exceeds intra-population correlation between low quality cells. This is no longer seen with 
metaVIPER predicted protein activity (C), indicating it to be a more robust measurement of 
heterogeneity and regulatory properties from single cells. 
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abundance combined with low sequencing depth. Based on a metric assessing the dynamic range 
of protein activity in different sub-clusters, metaVIPER significantly outperformed single-
regulon-based VIPER analysis on this dataset (Figure 3.8). Most importantly, metaVIPER 
correctly inferred the differential, tissue-specific activity of established lineage determinants at 
the single cell level (Figure 3.7B-J). For instance, PAX5 [Nutt, 1999], EBF1 [Lin, 2010] and E2A 
[Bain, 1994] showed significantly higher activity in B lymphocytes (one-tail, p < 10-10); MITF 
[Levy, 2006], CTNNB1 [Rubinfeld, 1997] and HMGB1 [Lotze, 2005] showed significantly 
higher activity in melanoma cells (one-tail p < 10-10); finally, BCL11B [Li, 2010], FOXP3 [Hori, 
2003] and TBET [Szabo, 2000] showed significantly higher activity in T lymphocytes (one-tail p 
< 10-10). Conversely, I could not detect significant gene expression differences for most of these 
genes (e.g. pHMGB1 > 0.9) in melanoma cells, or expression was barely detected at all (average 
transcripts per million < 1), see E2A in B lymphocytes or FOXP3 and TBET in T lymphocytes, 














Figure 3.7 Inference of protein activity for single cells profiled by [Tirosh, 2016]. (A) 
Annotated cell types (B: B lymphocyte T: T lymphocyte, M: melanoma cell) were separated 
by t-SNE analysis, using metaVIPER-inferred activity for all annotated transcriptional 
factors, co-transcriptional factors and signaling proteins. Boxplots show metaVIPER-
inferred activity, as well as gene expression for tissue- specific lineage markers, including 
PAX5 [Nutt, 1999], EBF1 [Lin, 2010] and E2A [Bain, 1994] for B lymphocyte (B-D), MITF 
[Levy, 2006], CTNNB1 [Rubinfeld, 1997] and HMGB1 [Lotze, 2005] for melanocyte (E-G), 
BCL11B [Li, 2010], FOXP3 [Hori, 2003] and TBET [Szabo, 2000] for T lymphocyte (H-J). 
While these markers are significantly differentially active in these tissues, they could not be 
effectively assessed at the single cell level, either because no mRNA reads were detected or 
because markers were not statistically significant in terms of differential gene expression. 
Boxplots showed the median, lower/upper whiskers and hinges of z-scores. 
Figure 3.8 metaVIPER integration outperforms analysis with single interactome. As 
shown in Figure 3.1, for a single cell type, the tissue-matched regulatory model usually gives 
the highest absolute protein activity inferences. That is to say, in a scenario where different 
cell types exist, the best regulatory model will give high variance of protein activity across 
the dataset. I compared the variance of protein activity inferences based on VIPER analysis 
across 27 distinct tissue-lineage contexts with that of metaVIPER integration. In all cases, 
metaVIPER outperformed the VIPER analysis. The figures show the ΔAUC between ecdf 
curve for a null model, built by uniformly shuffling the expression profile sample-wise 
(shown in black), and that of VIPER/metaVIPER analysis (shown in red), among which 
metaVIPER gives the highest value. 
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To provide a more systematic comparison of the improvements offered by metaVIPER analysis 
of single cells against approaches based on state-of-the art gene expression analysis algorithms, 
using the same mixture of T, B, and melanoma cells described in the previous section. Most 
methods designed to address the gene dropout issue in scRNA-Seq profiles are not intended to 
perform differential expression analysis of two individual cells but rather only of single cell 
subsets representing molecularly distinct clusters/subtypes [Kharchenko, 2014; Finak, 2015; Vu, 
2016]. To perform this analysis, I thus quantified single cell gene expression using RSEM [Li & 
Dewey, 2011], which pre-assembles sequencing reads into transcripts, thus providing more 
accurate single cell gene expression quantification [Vallejos, 2017]. I then assessed the fraction 
of single cell pairs from two distinct clusters (e.g., B and T cell related) that could recapitulate 
differentially expressed genes and differentially active proteins, as originally detected from their 
corresponding bulk cell populations. For each cluster, I generated “synthetic bulk” expression 
profiles by averaging 100 randomly selected single cells, based on which I generated “synthetic 
bulk” protein activity profiles. As shown in the corresponding t-SNE plots, synthetic bulk 
profiles from metaVIPER-inferred protein activity analysis (Figure 3.9B) were much tighter than 
those produced by gene expression analysis (Figure 3.9A), suggesting that VIPER-inferred 
protein activity is more reproducible across samples than mRNA expression. Finally, I assessed 
the fraction of the 100 most differentially expressed genes and differentially active proteins (as 
assessed from bulk sample analysis) that could be recapitulated in a given fraction of single cells 
when compared to the bulk expression of a different cluster (e.g., a single T-cell vs. all cells in 
the melanoma cluster). As shown in Figure 3.9C, differential activity (turquoise curve) 
significantly outperformed RSEM-based differential gene expression analysis (yellow curve). 
This becomes even more evident when considering pairs of differentially expressed genes or 
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active proteins (e.g., gene X and Y being both differentially expressed in a single cell if they are 
both differentially expressed in the bulk) (Figure 3.9D). The latter is important as it supports use 
of metaVIPER to generate analyses similar to what is normally accomplished by FACS, using 
two or more markers, using any of the ~6,000 proteins assessed by the algorithm not limited by 
antibody availability. This is shown in Figure 3.9E - J, where virtual FACS plots are shown for 
critical lineage markers of these populations using gene expression (top plots) or protein activity 
(bottom plots). As shown, it is virtually impossible to identify cell clusters based on selected 
marker-pairs at the gene expression level. Indeed, most of the cells are found either on the x-axis 
(no detectable expression of the Y-marker) or on the y-axis (no detectable expression of the X-
marker) or at the intersection of the two axes (no detectable expression of either marker). In 
contrast, metaVIPER analysis generates virtual FACS plots that are consistent with what would 
be produced by an actual FACS assay. For instance, consider CD19 and CD3, which are classic 
B and T cells markers, respectively. From metaVIPER analysis (Figure 3.9J), one can clearly 
identify a CD19+/CD3- cluster corresponding to B cells, a CD19-/CD3+ cluster corresponding to 
T cells, and a CD19-/CD3- cluster corresponding to melanoma cells. Yet, this is not possible 











Finally an additional value of the algorithm is that processes that are not consistent with the 
transcriptional regulatory architecture of the cells of interest are effectively filtered out by the 
interactome analysis. This is useful, for instance, in eliminating bias due to different chemistry of 
single-cell profiling or batch effects due to use of different gene expression quantification 
methodologies (Figure 3.10 and 3.11). This is helpful as these biases and batch effects represent 
a major obstacle to the integrative analysis of gene expression data generated in different labs or 
using slightly different reagent batches. 
Figure 3.9 Comparative analysis of single cell metaVIPER performance compared to 
gene expression based methods. I identified the 100 most differentially expressed genes and 
differentially active proteins based on the analysis of 5 synthetic bulk samples created by 
averaging the expression of 100 randomly selected single cells from the melanoma, B cell, 
and T cell population clusters, respectively. (A, B) Based on t-SNE analysis, synthetic bulk 
samples clustered more tightly when analyzed based on VIPER-inferred protein activity than 
based on gene expression. (C). This panel shows the percent of the top 100 most differentially 
expressed genes/active proteins recapitulated as significantly differentially expressed/active in 
a given fraction of individual cells against the average expression/activity in a distinct cluster 
(e.g., a T cell vs the average of all B cells). The yellow and turquoise curves (1-ECDF) and 
boxplots (median, lower/upper whiskers and hinges) summarized the results of RSEM and 
metaVIPER-based analyses, respectively. (D). The same analyses were repeated to assess 
reproducible differential expression/activity of a gene/protein pair, as relevant for virtual 
FACS analyses. (F-H) Virtual FACS analyses using expression and activity of established 
lineage marker TFs by RSEM and metaVIPER-based analysis (see main text and Figure 2.7 
for details). (I-K) Virtual FACS analysis using expression and activity of STAT4 and POU2F 
– both identified as differentially expressed and active candidate biomarkers from bulk 
sample analyses, – using the same methods. (L-N) Virtual FACS analysis based on expression 
and activity of CD3 and CD19 cell surface markers, as used in standard FACS analyses, using 










Taken together, these data show that metaVIPER represents a useful methodology for the 
analysis of single cell data and, in particular, for the identification of lineage specific regulatory 
programs and lineage markers in samples comprising a heterogeneous mixture of single cells. 
Figure 3.10 metaVIPER reduces discrepancies between different scRNA-Seq data 
sources. I analyzed filtered PBMC scRNA-Seq data generated using 10x Genomics V1 
(Black) and V2 (Blue) chemistry. To make them comparable, I randomly selected 200 single 
cells for each data sources. Discrepancies between different scRNA-Seq data sources were 
observed using expression, while no longer seen using metaVIPER prediction. 
Figure 3.11 metaVIPER reduces discrepancies between different expression 
quantification tools. I analyzed scRNA-Seq data reported by [Wu, 2014]. Transcriptomic 
profiles were quantified using STAR [Dobin, 2013] (Blue) and kallisto [Bray, 2016] (Black). 
Discrepancies between different expression quantification tools were no longer seen using 
metaVIPER predicted protein activity. 
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3.4 Discussion 
I have shown that integration of multiple interactomes using an evidence integration platform 
(metaVIPER) can provide accurate assessment of protein activity independent of tissue lineage. 
By systematic, I mean that activity of 6,000 proteins can be reproducibly assessed from any 
tissue, independent of their gene expression; this is especially valuable in single-cell analyses. 
MetaVIPER can thus help infer activity of key regulators in tissues lacking a matched 
interactome – either due to low sample availability (orphan tissues) or to lack of tissue lineage 
information – as well as in highly heterogeneous single cell populations isolated from bulk tissue. 
I propose a specific metric (ECDF|NES|) to assess whether a specific repertoire of interactomes is 
adequate for the metaVIPER analysis of an unknown or orphan tissue. 
MetaVIPER is especially useful for the study of single cell biology, as its results are largely 
independent of sequencing depth and allow quantitative inference of protein activity even when 
the corresponding mRNA is undetectable. Indeed, differential activity of established lineage 
markers of T, B, and melanoma cells could be clearly assessed in single cells from a complex 
mixture, even though most of these markers were either not detected or could not be identified as 
statistically significantly differentially expressed at the mRNA level. The reduction in bias and 
batch effects is an additional advantage, allowing integration of datasets from multiple labs or 
generated at different times, thus addressing the important issue of single-cell data 
reproducibility.  
Among the most obvious limitations of the method, metaVIPER cannot accurately measure 
activity of proteins whose regulons are not adequately represented in at least one of the available 
interactomes. This includes proteins whose targets are exceedingly tissue-specific within rare 
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tissue types and single cell sub-populations, for instance in liver hepatocellular carcinoma and 
testicular germ cell tumors. As more interactomes are assembled, including by ARACNe 
analysis of single cell data from homogeneous sub-populations, this limitation will be 
increasingly mitigated. This suggests that a concerted effort toward the generation of regulatory 
models representing distinct cellular compartments should be undertaken. 
It should be noted that, while I used ARACNe as a methodology for interactome generation, 
there are many alternative/complementary methods to accomplish the same goal, ranging from 
DNA binding-site analysis [Lachmann, 2010, Lachmann, 2010], to correlation-based [Butte, 
2000] and graphical-model-based [Friedman, 2004], to literature-based approaches [Kramer, 
2014]. Comparison of VIPER performance using several of these methods was already discussed 
in [Alvarez, 2016] and is thus not repeated here. In terms of the VIPER algorithm, as also 
discussed in [Alvarez, 2016], alternative algorithms to transform a gene expression profile into a 
protein activity profile are still lacking but a thorough performance comparison can be easily 
performed once they become available. In general, the metaVIPER approach is independent of 
the specific algorithms used for either interactome reverse engineering or analysis and should 
thus be still fully applicable once VIPER alternatives will emerge.   
I have shown that VIPER-based elucidation of MR proteins using tissue lineage-specific 
interactomes can effectively identify reprogramming and pluripotency factors [Carro, 2010; 
Kushwaha, 2015; Talos, 2017; Dutta, 2016] as well as determinants of tumor states [Aytes, 2014; 
Bisikirska, 2016; Carro, 2010] and resistance to targeted therapy [Rodriguez-Barrueco, 2015; 
Piovan, 2013]. As a result, application of metaVIPER to single-cell populations identified by 
cluster analysis could help identify critical determinants of lineage development as well as 
distinct dependencies within molecularly heterogeneous sub-population in cancer tissues. For 
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instance, it may help identify critical dependencies in chemoresistant cell niches, including rare 
tumor-initiating and tumor stem cell niches that have been shown to have poor sensitivity to 
standard chemotherapy and targeted therapy. Similarly, it could help identify drivers leading to 







iterClust: a Statistical Framework for Iterative 
Clustering Analysis [Ding, 2018b]
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4.1 Introduction 
In a scenario where two clusters may exist (A and B), with B further divided into two sub-
clusters (B1 and B2), the more pronounced differences between A and B may prevent subtle 
differences between B1 and B2 from being revealed. To solve this problem and to better describe 
the sub-cluster hierarchy, I propose to perform cluster analysis iteratively, such that individual 
clusters may be subdivided into smaller ones until further subdivisions are no longer statistically 
significant. Thus, for example, differences between A and B would lead to identification of two 
clusters in the first iteration, while B1 and B2 would be further identified in iteration 2. Previous 
effort in iterative clustering analysis [Usoskin, 2015] lacks systematic criteria in determining key 
clustering parameters, e.g. optimal number of clusters among iterations. The iterClust 
Bioconductor R package provides an unsupervised statistical framework for iterative clustering 
analysis, which can be used to, for instance discover biological heterogeneity, especially in 
single cell analyses of heterogeneous tissues, where cell lineages impose a relatively strong 
hierarchical structure, or solve general clustering problems. 
4.2 Methods 
4.2.1 iterClust framework 
R function iterClust() performs iterative clustering analysis by organizing user-defined functions 
in the following workflow: 
(1) ith iteration start 
(2) featureSelect(), select clustering features in this iteration. 
(3) clustHetero(), confirm observation sets to be splitted in this iteration are heterogeneous. 
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(4) coreClust(), for heterogeneous observation sets confirmed by clustHetero(), generate 
several clustering schemes. 
(5) clustEval(), choose the optimal scheme given by coreClust(). 
(6) obsEval(), evaluate how each observation is clustered. 
(7) obsOutlier(), poorly clustered observations are removed. 
(8) ith iteration end 
iterClust takes diverse feature selection methods [Saeys, 2007]; clustering algorithms, e.g. 
partition-based, hierarchy-based [Kaufman & Rousseeuw, 2009], density-based [Ester, 1996] 
and graph-based [Newman & Girvan, 2004]; and cluster/observation evaluation methods, e.g. 
sampling-based consensus score [Monti, 2003] or regular silhouettes score [Rousseeuw, 1987]. 
In addition, parameters for all user-defined functions can be set up as a function of the iteration, 
for instance, clustHetero() can be set up such that looser threshold parameters may be used as the 
iteration depth increases to deal with more and more subtle heterogeneity. In addition, 
featureSelect() can be used to select clustering features based on previous iterations. For instance 
this can help exclude features used to identify coarser clusters in prior iterations to unveil novel, 
more subtle heterogeneity at the current iteration. Taken together, these two functions make 
iterClust a highly flexible statistical framework for iterative cluster analysis. The results of 
iterClust are organized by iteration. Within a specific iteration, for each cluster, the 
corresponding observation names and clustering features are recorded, providing a 
comprehensive clustering trajectory. 
4.2.2 Data and software availability 




4.3.1 Running time and influencing factors of iterClust 
As a statistical framework, the running time, as well as influencing factors of iterClust is majorly 
dependent on the clustering algorithm in coreClust() function that is specified by the user. As an 
example, I benchmarked iterClust on a public human PBMC (Peripheral Blood Mononuclear 
Cell) scRNA-Seq dataset. The original dataset was sub-sampled into different sizes, and pam() 
function (Partition Around Medoids, in R package cluster) was used in coreClust() function. In 
this case, running time increases exponentially and linearly as number of cells and genes 





Figure 4.1 Running time and influencing factors of iterClust. Parameters used: pam() 
function (Partition Around Medoids, in R package cluster) in coreClust() function; k 
(number of clustering schemes generated within each iteration) was set as 2-5; number of 
iterations per-formed was set as 3. Running time increases exponentially and linearly as 
number of cells and genes increases, respectively (A), which agrees with the property of 
pam() function (B). Testing datasets with different sizes were generated by randomly 
subsampling cells and genes in the PBMC dataset. 
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4.3.2   Performance of iterClust in heterogeneity detection 
As shown in Figure 4.2, within the PBMC dataset, in the 1st iteration, iterClust identified T-cell 
and APC (Antigen Presenting Cell) clusters. In the 2nd iteration, the algorithm further separated 
the original 2 clusters into additional sub-clusters, including monocyte and B-cells in the APC 
cluster (monocyte and B-cell are two major types of APC), as well as effector T-cell and 
naïve/memory T-cells in the T-cell cluster. Critically, all clusters identified by the analysis were 
characterized by well-established cell-type-specific gene expression (Figure 4.3). The finer grain 
sub-division was not the optimal solution using single pass analysis (Figure 4.4). Taken together, 
iterClust can correctly elucidate complex hierarchical substructures that contribute to tissue 
heterogeneity in PBMC single cell dataset, with more pronounced differences in starting 
iterations, followed by relatively subtle differences, providing a comprehensive clustering 
trajectory. I further confirmed these conclusions on independent scRNA-Seq datasets (Figure 4.5 
and 4.6), as well as general benchmarking datasets for clustering analysis (Figure 4.7 and 4.8). 
 
Figure 4.2 Revealing cell types within human PBMC using iterClust. For illustration 
purpose, the data was projected on 2D-space with t-SNE plots [Maaten & Hinton, 2008], on 
which iterClust discovered clusters were colored. iterClust in 1st round (A) separated two 
major cell types, T-cell and APC (Antigen Presenting Cell) and 2nd round (B) further dissect 
these clusters, separating monocyte and B-cell in APC cluster, as well as Effector T-cell and 







Figure 4.3 PBMC dataset lineage marker annotations. Cells were projected onto 2D-
space as in Figure 4.2. Cluster IDs given by iterClust iteration 2 and annotated cell types 
were shown in A and B, correspondingly. (C, D, I, J) Markers for T-cells and APCs, which 
were separated in 1st iteration. (E-H) Markers for naïve/memory T-cells and effector T-cells, 
which were separated in 2nd iteration among the T-cell cluster. (K-N) Markers for 








Figure 4.4 Single pass analysis on the PBMC dataset. Cells were projected onto 2D-space 
as in Figure 4.2. PAM (Partition Around Medoids) clustering, as well as hierarchical 
clustering with predefined 2-5 clusters were performed as single pass clustering methods. 
The optimal clustering scheme was determined by maximum average silhouette score. In 
both cases k=2 was considered as optimal clustering scheme, where finer grain sub-division 










Figure 4.5 Tirosh human cutaneous melanoma (SKCM) dataset. This dataset contains 
single SKCM tumor cells, as well as infiltrating lymphocytes dissociated from different 
primary patient samples. For illustration purpose, the data was projected on 2D-space with t-
SNE plots [Maaten & Hinton, 2008]. The states of tumor cells are reported to be highly 
patient-specific while infiltrating lymphocytes are less patient-specific but heterogeneous 
[Tirosh, 2016]. Dataset was visualized as in main figure. Patient ID and annotated cell types 
were shown in A and B, correspondingly, B: B-cell, M: SKCM cell, T: T-cell. iterClust 
searched 3 iterations (D-F), the 1st iteration separated  immune cells from tumor cells, 
followed by reveling patient-specificity among tumor cells, and the 3rd iteration dissected 
immune cells, particularly separated B-cells from T-cells. As a comparison, result of single 
pass PAM clustering (used as coreClust() in iterClust) with pre-defined 18 clusters (same 








Figure 4.6 Usoskin mouse sensory neuron dataset [Usoskin, 2015]. For illustration 
purpose, the data was projected on 2D-space with t-SNE plots [Maaten & Hinton, 2008]. 
Annotated cell types were shown in A. iterClust searched 3 iterations (C-E), the 1st iteration 
separated TH, NP and NF-PEP cell populations, followed by revealing subpopulations 
among NF and PEP cells in 2nd and 3rd iterations. As a comparison, result of single pass 
PAM clustering (used in coreClust() in iterClust) with pre-defined 8 clusters (same with 
iterClust round 3) was shown in B, where NF heterogeneity were not fully appreciated, 







Figure 4.7 Dim1024 dataset [Fränti, 2006]. The dataset contains N=1024 observations, 
D=1024 features and k=16 Gaussian clusters, which represents general clustering problem. 
For illustration purpose, the data was projected on 2D-space with t-SNE plots [Maaten & 
Hinton, 2008]. iterClust searched 3 iterations (B-D), and all 16 clusters were correctly 
discovered at 3rd iteration. As a comparison, result of single pass PAM clustering (used in 
coreClust() in iterClust) with pre-defined 16 clusters was shown in A. 
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Figure 4.8 Aggregation dataset [Gionis, 2007]. The dataset contains N=788 observations, 
D=2 features and k=7 clusters, which represents low-dimensional clustering problem. 
Density-based clustering algorithms DBSCAN [Ester, 1996] and successors OPTICS, which 
takes into account local point density [Ankerst, 1999] were designed for low-dimensional 
clustering problem. Here, I compared iterClust (B-D), with single pass hierarchical 










Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults with 
unsatisfactory prognosis [Ohgaki & Kleihues, 2005]. Prognosis of GBM, as previously shown, is 
associated with tumor molecular features [Ceccarelli, 2016; Freije, 2004; Liang, 2005; Murat, 
2008; Nutt, 2003; Phillips, 2006; Verhaak, 2010; Wang, 2017]. Based on these molecular 
features, GBM has been clustered in distinct subtypes based on two major competing schemes, 
as described in [Phillips, 2006] and [Ceccarelli, 2016; Verhaak, 2010] with the most recently 
correction [Wang, 2017]. I propose that the observed inter-tumor heterogeneity, as defined by 
these classification schemas, is the direct result of intra-tumor heterogeneity at the single cell 
level [Burrell, 2013]. In addition, all previously proposed classification analysis were done 
within specific subsets of whole transcriptome, therefore may not be effectively recapitulated by 
truly unsupervised clustering methods. Even more troubling, while all classification algorithms 
are probabilistic in nature, the specific probabilities representing the likelihood that individual 
tumors may belong to one of the classes, e.g. Wang Proneural (wPN), Mesenchymal (wMES) or 
Classical (wCL), are not generally disclosed. Indeed, as shown by my analysis, a large number of 
tumor samples or single cells have probabilities that are almost identical for two and even all of 







Figure 5.1 Cross-annotation between Wang and Phillips classifiers. For both Wang (A) 
and Phillips (A) datasets, samples were ordered according to classification confident scores 
(SIMS), which were determined in the original studies. The normalized expression of 
subtype-defining genes in their corresponding datasets (B, F) and their counterpart (C, G), 
was shown in the heatmaps. The cross-annotation panels showed the likelihood of being 
each subtype, which was measured by the relative proportion of GSEA (Gene Set 










Table 5.1 Summary of different clustering schemes for Patel single cell dataset. 
  #Cells Mean Silhouette   #Cells Mean Silhouette 
k=2 Cluster1 236 0.32 k=3 Cluster1 158 0.28 
 Cluster2 194 0.28  Cluster2 110 0.40 
     Cluster3 162 0.44 
 Total 430 0.30  Total 430 0.37 
k=4 Cluster1 157 0.23 k=5 Cluster1 108 0.21 
 Cluster2 94 0.39  Cluster2 64 0.21 
 Cluster3 59 0.05  Cluster3 93 0.34 
 Cluster4 120 0.32  Cluster4 57 0.03 
     Cluster5 108 0.29 
 Total 430 0.27  Total 430 0.23 
 
To address some of these issues, recent work has attempted to directly tackle the issue of intra-
tumor GBM heterogeneity by single cell RNA sequencing (scRNA-Seq) profiling and 
classification [Darmanis, 2017; Patel, 2014; Wang, 2017]. However, these approaches suffer 
from several limitations. First, single cells are generally profiled at low depth, making 
classification efforts less effective due to significant technical noise [Kolodziejczyk, 2015]. 
Second, most of these efforts have attempted to classify single cells according to previously 
Figure 5.2 Classification analysis on Patel single cell dataset. Pairwise similarity between 
single cells at protein activity level [Alvarez, 2016] was shown in A. Each single cell was 
annotated with Phillips, Wang as well as single cell subtype-specific marker sets separately 
(see Methods). The likelihood of being each subtype, which was measured by the relative 
proportion of GSEA scores, is shown in the C. Percentage of cells that were uniquely 
annotated was shown by UniAnno, which is considered as an evaluation of robustness of 
GSEA sets. The subtype with the largest relative proportion of single cell scores was 
considered as the single cell subtype of each cell, which was presented in B. The samples 
were clustered using PAM method with k = 3 as optimal scheme determined by silhouette 
scores (Table 5.1), which was also presented in B. Proportion of MES and PN single cells, as 
well as proportion of Proliferative cells in each primary patients was shown in D. Wang 
classification of five bulk primary patients samples, which was determined in the original 
study was color-coded. Annotation of Wang and Phillips datasets using derived single cell 
subtype-specific marker sets was shown in E and F respectively. 
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reported bulk profile schemas, rather than learning the classification from scratch. Finally, single 
cells taken from a human context or following passaging as neurosphere are either mixed with 
non-tumor subpopulations, whose identity may be different to assess, or are more likely to 
recapitulate specific subtypes.  
To address the first two issues, I used a fully unsupervised classification methodology, based on 
the metaVIPER algorithm [Alvarez, 2016; Ding, 2018a], which does not require any a priori 
gene-set selection. Specifically, metaVIPER computes the activity of ~2,000 transcription factors 
(TFs) based on the expression of their transcriptional targets, as identified by the algorithm for 
the Accurate Reconstruction of Cellular Networks (ARACNe) algorithm. Several studies 
[Alvarez, 2016; Aubry, 2015; Bisikirska, 2016; Brichta, 2015; Della Gatta, 2012; Ikiz, 2015; 
Kushwaha, 2015; Lefebvre, 2010; Repunte-Canonigo, 2015; Rodriguez-Barrueco, 2015; Talos, 
2017], including in GBM [Carro, 2010; Chen, 2014; Chudnowski, 2014; Ding, 2018a] have 
shown that protein activity predicted by metaVIPER or its precursor MRA (Master Regulator 
Analysis) from transcriptomic profiles are more robust descriptors of biological states. Indeed, 
fully unsupervised, metaVIPER-based single cell analysis recapitulates the TFs that were 
originally reported and experimentally validated as master regulators of the MES-PN transition 
at the single cell level [Carro, 2010]. For the third issue, I harvested tissue from PDX models 
established at the Mayo Clinic, by orthotopic transplantation of florescent protein labeled GBM 
patient tissue. I specifically selected models that had been originally classified (before 
transplantation) as representative of all subtypes described in [Verhaak, 2010; Wang, 2017]. This 
approach effectively removes contamination by microenvironment related cells, which are 
rapidly replaced by murine cells. Based on these analyses and on de novo classification of single 
cells, independent of previously reported classification schemas, I report three key findings. First, 
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GBM cells implement a bi-stable state characterized either by a MES or PN signature with a 
more or less proliferative (Prolif) phenotype, including when considering cells from samples 
previously classified as wCL. Second, the new analysis provides virtually unequivocal 
classification (>90% of single cells), compared to previous schemas (Wang and Phillips) that 
only unequivocally classify ~55% of individual cells. Second, previously reported bulk-tissue 
classification schemas can be fully recapitulated by a mixture of MES and PN cells with 
different degrees of proliferative potential. Finally, I report that single cell state evolves during 
passaging in PDX models resulting in increasingly lower single-cell heterogeneity fidelity at 
higher passages. Taken together, the first two findings provide a potential rationale for the 
current classification discrepancies, as well as a more definitive classification schema. Indeed, 
these findings suggest that virtually every GBM comprises a PN and a MES niche, with varying 
degrees of proliferative potential, thus requiring the use of subtype-targeted combination therapy 
supplementing the current standard of care (radiation + temozolemide), which is mostly targeting 
cells with the higher proliferative potential. The third finding suggests that extreme caution 
should be used when using PDX models of GBM, as their ability to recapitulate the original state 
of the patient tumor is likely affected at later passages. 
5.2 Methods 
5.2.1 Cell line generation 
GFP-expressing derivatives of patient derived xenografts were established by transducing short-
term explant cultures with lentivirus as previously described [Gupta, 2014; Gupta, 2016]. 
Transduction efficiency was evaluated by examining the extent of GFP positivity by fluorescent 
microscopy before cell expansion in an athymic nude mouse.  
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5.2.2 Intracranial implantation 
GFP-expressing cell lines were harvested from flank tumors of athymic nude mouse and placed 
on Matrigel (BD Biosciences, Billerica, MA) coated plates. Once cells were adherent, GFP 
positivity was confirmed by fluorescent microscopy and cells were prepped for intracranial 
injection. Cells were stereotactically injected into the right hemisphere of each athymic nude 
mouse. Animals were monitored daily and sacrificed by cervical dislocation at the onset of 
neurological decline. 
5.2.3 Tumor dissociation 
Following cervical dislocation, brains were removed and tumors carved using goggles equipped 
with GFP visualization (BLS Limited, Budapest, Hungary). Tumors were placed into Eppendorf 
tubes containing DMEM media (Corning, 10-013-CV) and immediately processed for 
dissociation. Tumor specimens were rinsed with PBS and trypsinized (TrypLE, ThermoFisher, 
Waltham, MA). The tissue was then minced into small fragments using dissection scissors and 
placed in a 37 degree waterbath, vortexing periodically. The solution was spun at 1200 rpm for 3 
minutes, trypsin was removed, and the tissue pellet was resuspended in DMEM. The specimens 
were aspirated into 1 mL syringes and passed through 21G and 23G needles (Cardinal Health, 
Dublin, OH) until no clumps were visible. This solution was then filtered using 100 and 40 µm 
filters (ThermoFisher, Waltham, MA). Viability and single cell state of isolated cells was 
conducted by trypan blue exclusion and light microscropy. Finally, cells were spun down, 
washed twice in PBS, and immediately submitted to Mayo Clinic’s Core for Single Cell sorting.  
5.2.4 Single cell RNA sequencing 
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The cells were counted and measured for size and viability using the Vi-Cell XR Cell Viability 
Analyzer (Beckman-Coulter, Brea, CA). A C1 Single-Cell Array Integrated Fluidics Circuit (IFC) 
for mRNA-Seq (cell size 5-10 uM, Fluidigm product number 100-5759; cell size 10-17 uM, 
Fluidigm part number 100-5760) was primed in the C1 Single-Cell Auto Prep System (Fluidigm 
product number 100-7 000). While the IFC was being primed, the lysis, reverse transcription and 
PCR reagents were thawed and the respective chemistries were mixed in a clean room DNA-free 
hood. After priming, the IFC was taken to a cell culture hood and the cells were pipetted into the 
IFC. The IFC was placed back into the C1 System to load and separate the cells. Once the cells 
were sorted into up to 96 separate chambers, the IFC was removed from the C1 System and 
imaged on a microscope. Cell number and viability were noted on a log sheet. The lysis, reverse 
transcription and pre-amplification chemistries were pipetted into the IFC in the cell culture hood. 
The IFC was loaded into the C1 a final time to run the mRNA-Seq script overnight. 
The following morning, up to 96 individual cDNA samples were harvested from the IFC. All 
samples were quality control tested and quantified on a 96-capillary array Fragment Analyzer 
(Advanced Analytical, Ankeny, IA). Smear analyses were run using the PROSize® 2.0 software 
(Advanced Analytical). Only samples that passed the smear analysis thresholds were selected for 
library construction. Each of these samples was diluted to between 200-250 pg/ul. The Illumina 
Nextera XT DNA Library Preparation Kit (Illumina product number FC-131-1096) was used to 
create individually indexed cDNA libraries for sequencing. 
5.2.5 scRNA-Seq gene expression analysis 
After demultiplexing, the resulting raw reads were aligned to hg19 reference index by Bowtie2-
2.2.6 [Langmead & Salzberg, 2012]. Aligned reads were sorted and indexed by samtools-1.2 [Li, 
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2009]. Counts matrix was measured with R package GenomicFeatures-1.24.5 and 
GenomicAlignments-1.8.4 [Lawrence, 2013] and TxDb.Hsapiens.UCSC.hg19.knownGene-3.2.2 
[Carlson & Maintainer, 2015] from Bioconductor. 
5.2.6 Microarray gene expression analysis 
Informative probe clusters were assembled with the cleaner algorithm [Alvarez, 2009] and the 
expression data was summarized and normalized with the MAS5 algorithm as implemented in 
the R package affy-1.54.0 from Bioconductor [Gautier, 2004]. Differences in sample 
distributions were removed with the robust spline normalization procedure implemented in the R 
package lumi-2.28.0 from Bioconductor [Du, 2007; Du, 2008; Lin, 2008; Du, 2010]. 
5.2.7 Regulatory networks and protein activity profiles 
All 5 brain tumor regulatory networks were reverse engineered by ARACNe [Basso, 2005; 
Lachmann, 2016] with 100 bootstrap iterations using 1,813 transcription factors (genes annotated 
in Gene Ontology molecular function database. as GO:0003700, 'transcription factor activity', or 
as GO:0003677, 'DNA binding', and GO:0030528, 'transcription regulator activity', or as 
GO:00034677 and GO: 0045449, 'regulation of transcription'). Parameters were set to 0 DPI 
(Data Processing Inequality) tolerance and MI (Mutual Information) p-value threshold of 10-8. 
Protein activity profiles were inferred from expression matrix by integrating the 5 regulatory 
networks with metaVIPER [Alvarez, 2016; Ding, 2018]. 
5.2.8 Gene set enrichment analysis (GSEA) 
Phillips and Wang subtype-specific highly expressed gene sets were downloaded from the 
original studies [Phillips, 2006; Wang, 2017]. Single cell subtype-specific activated protein sets 
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were built with metaVIPER-inferred protein activity profiles from dataset GSE57872 [Patel, 
2014]. Only characteristic single cells (silhouette score > 0.5) were included. 10e-3 was used as 
p-value cutoff. 
In dimension #1 (MES-PN): 
MES protein set = t-test(MES, PN, alternative = "greater") 
PN protein set = t-test(PN, MES, alternative = "greater") 
In dimension #2 (Prolif): 
Prolif protein set = t-test(Prolif, non-Prolif, alternative = "greater") 
With the above-mentioned signatures, GSEA was performed with a costumed R function. 
5.2.9 Data and software availability 
The expression data reported in this study has been deposited in GEO under the accession 
number GSE107978.  
5.3 Results 
5.3.1 Cross-annotation between Phillips and Wang classifiers clarifies GBM inter-tumor 
heterogeneity 
To compare the Phillips [Phillips, 2006] and Wang [Ceccarelli, 2016; Verhaak, 2010; Wang, 
2017] classification schemes, in Figure 5.1, I used the published Phillips classifier to annotate 
Wang dataset and vice versa (see Methods). I first ordered the samples according to their 
classification confident scores, which were determined in the original studies (Figure 5.1A and 
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E). Then I showed the normalized expression of subtype-specific markers (Figure 5.1B and F), 
recapitulating results presented in the original studies. The expression of subtype-specific 
markers in cross-annotation analyses (Figure 5.1C and G) showed 1) Wang Mesenchymal 
(wMES) overlaps with Phillips Mesenchymal (pMES); 2) Wang Proneural (wPN) samples 
express both Phillips Proneural (pPN) and Proliferative (pProlif) markers, while Wang Classical 
(wCL) samples tend to only have higher expression on pPN markers; 3) pPN samples express 
both wPN and wCL markers; 4) pProlif samples express all three Wang marker sets. The cross-
annotation results were further summarized in Figure 4.1D and H, where the likelihood of being 
each subtype was presented. Taken together, cross-annotation results indicated MES (including 
wMES and pMES) and PN (including wPN, wCL and pPN) are real GBM inter-tumor molecular 
subclasses, while Prolif potential is an independent dimension besides MES-PN heterogeneity. 
Specifically, high Prolif potential with PN feature constitutes wPN subtype, while low Prolif 
potential with PN feature constitutes wCL and pPN subtypes. 
5.3.2 Classification analysis with single cells reveals GBM intra-tumor heterogeneity 
Previously studies in Dr. Califano lab have shown that transcriptional regulators activity profiles 
inferred from gene expression are more robust descriptors of biological states, especially for 
single cells, whose transcriptomic profiles are usually confounded by high level of technical and 
biological noises [Alvarez, 2016; Ding, 2018]. Therefore, to better study the molecular 
subclasses of GBM tumor cells, I converted published GBM single cell expression data obtained 
from primary tumor classified as all three Wang subtype (Figure 5.2D) [Patel, 2014; Wang, 2017] 
to protein activity profiles (see Methods) using metaVIPER integration of 5 available GBM 
ARACNe networks (Table 5.2). PAM (Partitioning Around Medoids) clustering was performed, 
and silhouette score suggested k=3 to be the optimal scheme (Table 4.1). To further study the 
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characters of each single cell subclasses, I used published Phillips and Wang classifiers to 
annotate each cluster (Figure 5.2A and C). Result showed two clusters were annotated as MES-
like (annotated as wMES or pMES) and PN-like (annotated as wPN/wCL or pPN), while the 
third cluster was composed of cells showed high Prolif potential, suggesting regardless of inter-
tumor subtypes, GBM is essentially composed of MES-like and PN-like tumor cells (I named 
them MES and PN single cells) with varying Prolif potential. I confirmed the above conclusions 
by analyzing an independent GBM scRNA-Seq dataset (Darmanis, 2017; see Figure 5.3A). 
Based on this, I built subtype-specific activated protein sets from single cells (see Methods) and 
previously validated MES-associated master regulators were recapitulated in MES-specific 
activated regulator sets, including STAT3, C/EBPB, FOSL2, bHLH-B2 and RUNX1 [Carro, 2010]. 
Table 5.2 Summary of used brain tumor regulatory networks. 
Expression Source # Samples # Regulators # Targets # Interactions 
TCGA RNA-Seq (Verhaak) 166 1811 18354 259025 
REMBRANDT 804 1265 11909 329695 
Phillips 176 835 8263 252082 
TCGA affymetrix 202 938 9162 272520 
TCGA agilent 202 1675 16115 748366 
 
To further associate GBM intra- and inter-tumor subclasses, I first annotated Wang and Phillips 
samples with classifier derived from above single cell analysis (Figure 4.2E and F, Figure 5.4). 
Consistent with cross-annotating analysis of Wang and Phillips datasets in previous session, 
MES (wMES and pMES) and wPN/wCL/pPN tumors are essentially MES and PN subtypes, 
while wPN/wCL tumors are PN with high/low Proliferative potential, respectively. I then, on the 
other hand, decomposed bulk primary tumors by showing the proportion of MES and PN cells, 
as well as proportion of Proliferative cells described on independent dimension besides MES-PN 
	 69	
heterogeneity, in each patient (Figure 5.2D). Results suggested that wMES patients (MGH28 and 
29) are dominated (>80%) by MES cells, while wPN and wCL patients (MGH26, 30 and 31) are 
dominated (>70%) by PN cells. Results also suggested wPN patient (MGH26) has higher 
proportion of Prolif cells (~90%) compared to other patients (on average ~30%). Taken together, 
these results suggested inter-tumor MES and PN subtypes are caused by dominating proportion 
of MES and PN tumor cells, respectively. Also, consistent with cross-annotating analysis of 
Wang and Phillips datasets in previous section, usually MES tumors are less Proliferative, while 








Figure 5.3 Classification analysis on Darmanis single cell dataset. A) Single cells were 
presented on a scatterplot showing heterogeneity and proliferating. Specifically, the 
distribution Prolif scores was showed in B. (C-E) Single cells were projected on 2-D space 
according to their GSEA scores towards Phillips subtypes (C), Wang subtypes (D), and 
single cell features (E) using MDS respectively (F-H, corresponding original 3-D space 
before projection), and color-coded according to subtypes determining by the corresponding 





5.3.3 Evaluation of Phillips, Wang and single cell classifiers 
To evaluate the performance of Phillips, Wang and single cell classifiers, I measured their 
capability in giving mutual-exclusively annotation towards single cells in [Patel, 2014] dataset. 
Specifically, on scatterplots I show the GSEA scores towards Wang (Figure 5.5A-C) and Phillips 
subtypes (Figure 5.5D-F), in a pairwise manner. Both Wang and Phillips classifiers gave “double 
Figure 5.4 Classification analysis on bulk datasets. Wang and Phillips dataset was 
visualized using 2-D MDS-projection. Specifically, the distribution of Prolif scores was 
showed in B and D, respectively.  
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positive” cells, e.g. wMES-wPN cells in 1st quadrant of Figure 5.5A, and pMES-pPN cells in 1st 
quadrant of Figure 5.5B. One the other hand, with my single cell classifier, ~95% single cells 
either fall into 2nd or 4th quadrant of Figure 4.5G, suggesting they were mutual-exclusively 
annotated as PN or MES, which is consistent with my previous conclusion that MES and PN are 
real subtypes of GBM tumor cells. Since I also concluded Prolif potential as independent 
dimension besides MES-PN heterogeneity in describing GBM tumor cells, I visualized the two 
dimensions in Figure 5.5H, giving a comprehensive description of the tumor cell states. 
I also projected single cells on 2-D MDS (Multi-Dimensional Scaling) space according to their 
GSEA scores towards Wang, Phillips, and my single cell classifiers, respectively (Figure 5.6B, D 
and F. Positions of cells in original 3-D GSEA space before MDS-projection were shown in A, C 
and E). Ideally, a good classifier should give clear separation of single cells on 2-D space, 
agreeing with their corresponding subtypes determined by this specific classifier, e.g. the single 
cell classifier, where the 1st dimension denoted MES-PN heterogeneity and 2nd dimension 
presented Prolif potential on 2-D MDS plot (Figure 5.6F). In contrast, annotation given by both 
Phillips and Wang classifiers didn’t agree well with 2-D cell projection, e.g. in Wang classifier, 
annotated wMES cells subdivided into two groups, among which one group co-segregated with 
annotated wPN cells and the other group co-segregated with annotated wCL cells (Figure 5.6B); 
in Phillips classifier, for the two major cell clusters, one contained cells annotated as all Phillips 
subtypes, and the other one was composed of pPN and pProlif cells (Figure 5.6D). Taking 
together, results suggested single cell classifier gave clear classification thereby outperformed 
the other two. I further confirmed the above conclusions by analyzing an independent GBM 







Figure 5.5 Evaluation of Phillips, Wang and single cell classifiers. GSEA scores towards 
Wang subtypes (A-C) and Phillips subtypes (D-F) were shown in a pairwise manner on 
scatterplots. For single cell classifier, GSEA scores towards PN and MES subtypes were 
shown in G, and projections of single cells onto Prolif potential dimension (GSEA score of 
Prolif) and MES-PN heterogeneity dimension (GSEA score towards MES minus that of PN) 
were shown in H. If the absolute projection on heterogeneity dimension was smaller than 2 
(within the two vertical lines, corresponds to p-value < 0.05), then the cell was considered as 
“unclassified”. Horizontal line denoted Prolif-score equals to 0. Cells reside above which 





5.3.4 “Passage-effect” when passaging GBM in mouse primary xenograft models  
GBM mouse patient derived xenograft (PDX) models, which are established by engrafting 
patient tumor specimens into the flank of nude mice and subjected to subsequent serial passaging, 
are important for advancement of basic and translational biology [Carlson, 2011]. Therefore it’s 
critical to examine 1) whether PDX models preserve GBM heterogeneity and 2) whether serial 
passaging deviates tumor features. To explore both points, Dr. Sarkaria lab generated scRNA-
Seq profiles from mouse PDX models (Mayo dataset, Table 5.3, Figure 5.7A and B). I annotated 
these single cells with Phillips, Wang and previously built single cell classifier (Figure 5.8). 
Followed the same analysis done in Figure 5.6, I showed only single cell classifier gave clear 
separation of the profiled cells (MES and PN), confirming its superior performance against 
Figure 5.6 Patel dataset visualized in original 3-D GSEA space and 2-D MDS- space. 
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Phillips and Wang classifiers, as well as GBM is essentially composed of MES and PN cells, 
further suggesting mouse PDX models preserve both MES and PN tumor single cells. However, 
as passaged in mouse PDX, I observed decreasing MES proportion (Figure 5.7C) and increasing 
Prolif potential, compared to primary cells (Figure 5.5H and Supplemental Figure 5.3A where 
~60% profiled cells were annotated as non-Prolif cells), suggesting deviation in GBM molecular 
feature when undergoing serial passaging. 
Table 5.3 Summary of processed GBM samples provided by Mayo Clinic. 
Sample ID Source Data Type Verhaak Subtype Passage #Cells 
G12 PDX scRNA-Seq NL >P10 87 
G22 PDX scRNA-Seq NL P6 52 
G38 PDX scRNA-Seq CL P1 56 
G38 PDX scRNA-Seq CL P6 31 
G43 PDX scRNA-Seq MES P15 43 
G84 PDX scRNA-Seq NL P3 64 





Figure 5.7 Annotating single cells obtained from mouse PDX models. (A) Profiled single 
cells (Table 4.3) were presented on scatterplots. Verhaak and Wang classification of primary 
patients where the mouse PDX models were derived (A), IDs (B) and passage status (C) were 
also shown. Specifically, in C, I highlighted the early (P1) and late (P6) passages for Classical 





Taken together, the study suggested that GBM is composed of MES and PN tumor cells with 
different Prolif potentials, these cells mix at varying ratio and cause different inter-tumor features 
(Figure 4.9A). Considering previous study in Califano lab `suggested MES and PN are 
interchangeable by perturbing five master regulators [Carro, 2010], therefore therapeutic 
strategies should target MES and PN tumor cells at the same time as well as considering the 
Prolif potential, and these findings would be great value for developing novel therapeutic 
strategies. I also showed “passage-effect” (Figure 4.9B) that molecular features of GBM drifts as 
Figure 5.8 Mayo dataset visualized in original 3-D GSEA space and 2-D MDS- space. 
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mouse PDX passaged, suggesting mouse PDX model should be used with cautious and early 
passage is preferred. 
 
Figure 5.9 Graphic summary. (A) Inter-/intra-tumor heterogeneity: GBM is composed of 
MES and PN tumor cells. Besides heterogeneity, tumors cells also have various Prolif 
potential, which is considered a second dimension of tumor features. These single cells mix at 
various ratios thereby causes GBM inter-tumor heterogeneity. Specifically, tumors dominated 
by MES cells are considered as wMES or pMES subtypes, tumors dominated by cells with 
high Prolif feature are considered as pProlif subtypes, tumors dominated by Prolif PN cells 
are considered as wPN subtypes, and tumors dominated by non-Prolif PN cells are considered 
as wCL or pPN subtypes. (B) “Passage-effect”: PN cell proportion and Prolif potential 






Elucidating Regulators of β-cell De-
Differentiation in Type-2 Diabetes
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6.1 Introduction 
Type 2 Diabetes (T2D) is associated with defective β-cell insulin secretion and subsequent 
reductions of β-cell mass. Unveiling the mechanisms that control β-cell dysfunction is of 
fundamental importance towards understanding the pathophysiology of human T2D [Prentki & 
Nolan, 2006]. Conventionally, apoptosis has been thought of as a major pathway to loss of β-cell 
mass in T2D [Butler, 2003]. Recent studies using rodent models have shown that 
dedifferentiation of mature β-cells into endocrine progenitor-like cells can also play a role in this 
process [Talchai, 2012]. However, it is unclear whether similar de-differentiation process can 
cause β-cell failure in human T2D. To solve this problem, I combined single cell RNA 
sequencing (scRNA-Seq) technique [Kolodziejczyk, 2015] with master regulator analysis 
[Califano & Alvarez, 2017] to have higher resolution characterization of β-cells under de-
differentiation state, as well as discovering de-differentiation related master regulators. Dr. Son 
also performed functional validation of the discovered mater regulators by testing whether they 
can reprogram health β-cells to de-differentiated cells, or even α-cells. 
6.2 Methods 
6.2.1 Sample collection and islet dissociation 
In total Dr. Son collected islet samples from 11 donors, see Table 6.1 for detail. Human primary 




Table 6.1 Sample information 
Donor ID Sex Age BMI HbA1C 
Normal20151026 M 25 26.0 NA 
Normal20160224 F 51 20.1 NA 
Normal20160310 F 53 34.0 NA 
Normal20160427 F 36 23.5 5.00% 
Patient20160121 M 48 43.7 6,60% 
Patient20160202 M 51 24.6 6.90% 
Patient20160303 F 42 27.6 6.70% 
Patient20160314 M 59 32.5 6.60% 
Patient20160707 M 58 39.3 8.90% 
Patient20160712 M 59 31.6 9.60% 
Patient20160714 F 62 30.4 6.60% 
 
6.2.2 Enrichment of β-cells 
The freshly dispersed islet cells were submitted to auto fluorescence-activated cell sorting using 
an influx cell sorter (BD Biosciences), illuminating the cells at 488 nm, so that the emission at 
510-550 nm could be taken as a parameter for their flavin adenine dinucleotide (FAD) content. 
Selection of appropriate gates allowed the simultaneous isolation of single beta and single non- 
beta islet cells since β-cells displayed higher FAD fluorescence than single non-β cell. 
6.2.3 Over-Seq experiment 
Over-Seq was designed for gain-of-function studies, testing whether putative de-differentiation 
master regulators can reprogram health β-cells to de-differentiated cells, or even α-cells. In 
contrast to Cas9-mediated knockout, Cas9-mediated gene activation in the endogenous locus 
often results in variable and non-robust outcomes in different systems, possibly due to difficulty 
of accessing compacted chromatin of transcriptionally inactive genes (heterochromatin) [Gilbert, 
2014]. Therefore Dr. Son generated tools to express bicistronic candidate genes and BFP reporter 
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followed by a unique 18-nt barcode. Similar to Perturb-Seq [Dixit, 2016], by introducing a 
mixture of viruses with individual barcodes for each cDNA in individual cells, I can determine 
the effect of overexpression on β-cell fate conversion. To facilitate the cloning of these libraries, 
Dr. Son used pENTR gateway system (Thermo Fisher) that enables systematic and simple 
insertion of candidate cDNA into adenovirus expression plasmids. 
6.2.4 Single cell RNA sequencing 
Primary single cells were processed following standard C1 Single-Cell Auto Prep System 
protocol, using medium (10-17 uM) 800-capture-sites C1 Single-Cell Array Integrated Fluidics 
Circuit (IFC). Over-Seq perturbed single cells were processed following standard 10x Genomics 
Chromium protocol. 
6.2.5 scRNA-Seq gene expression analysis 
For primary single cells profiled by C1 system, after demultiplexing, the resulting raw reads 
were aligned to hg19 reference index by Bowtie2-2.2.6 [Langmead & Salzberg, 2012]. Aligned 
reads were sorted and indexed by samtools-1.2 [Li, 2009]. Counts matrix was measured with R 
package GenomicFeatures-1.24.5 and GenomicAlignments-1.8.4 [Lawrence, 2013] and 
TxDb.Hsapiens.UCSC.hg19.knownGene-3.2.2 [Carlson & Maintainer, 2015] from Bioconductor. 
For Over-Seq perturbed single cells profiled 10x Genomics Chromium, gene expression profiles 
were quantified using standard 10x Genomics Cell Ranger pipeline. 
6.2.6 Over-Seq barcode quantification 
10x Genomics Cell Ranger pipeline allows multi-mappers, therefore not able to give precise 
quantification of Over-Seq barcodes, due to identical regions among the barcode sequences. To 
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solve this problem I used customized analysis pipeline to quantify Over-Seq barcodes. Since 
Chromium follows similar barcoding and library construction strategy as scPLATE-Seq (the 
only differences are length of cell barcode, 16nt for Chromium and 8 for scPLATE-Seq, and 
length of UMI, 10nt for Chromium and 8nt for scPLATE-Seq), therefore I used scPLATE-Seq 
analysis pipeline for demultiplexing and UMI quantification with correct cell barcode and UMI 
length parameters. After demultiplexing, reads were aligned and mapped to UCSC hg38 genome 
using the STAR 2.6.1a [Dobin, 2013] with option --quantMode TranscriptomeSAM so that 
output alignments are translated into transcript coordinates for downstream analysis, --
clip5pNbases 10 so that the UMI sequences are not mapped, and --outFilterMultimapNmax 1 so 
that only reads that uniquely mapped are considered. All other options for STAR are set as 
default. Then the mapped transcripts per gene were quantified with hamming distance threshold 
1. Note that the above procedures are only for quantifying Over-Seq barcodes. Gene expression 
of the Over-Seq perturbed single cells were quantified by standard 10x Genomics Cell Ranger 
pipeline. 
6.2.7 Regulatory networks and transcriptional regulator activity inference 
The 11 (4 healthy and 7 diabetic) donor-specific regulatory networks were reverse engineered by 
ARACNe [Basso, 2005]. ARACNe was run with 100 bootstrap iterations using 1,813 
transcription factors (genes annotated in Gene Ontology molecular function database, as 
GO:0003700, 'transcription factor activity', or as GO:0003677, 'DNA binding', and GO:0030528, 
'transcription regulator activity', or as GO:00034677 and GO: 0045449, 'regulation of 
transcription'), 969 transcriptional cofactors (a manually curated list, not overlapping with the 
transcription factor list, built upon genes annotated as GO:0003712, 'transcription cofactor 
activity', or GO:0030528 or GO:0045449) and 3,370 signaling pathway related genes (annotated 
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in GO Biological Process database as GO:0007165 'signal transduction' and in GO cellular 
component database as GO:0005622, 'intracellular', or GO:0005886, 'plasma membrane'). 
Parameters were set to 0 DPI (Data Processing Inequality) tolerance and MI (Mutual Information) 
p-value (using MI computed by permuting the original dataset as null model) threshold of 10-8. 
The transcriptional regulator activity was inferred from gene expression signature by integrating 
the 11 donor-specific regulatory networks using the metaVIPER algorithm [Ding, 2018]. 
Specifically, for primary single cells, gene expression signature was generated by internal 
normalization within all profiled cells so that for each gene, the relative position of a specific 
single cell compared to all profiled cells was represented: for raw expression matrix described in 
6.2.6, first do column-wise rank transformation, followed by extracting row-wise median and 
mad values, then use (rank-median)/mad as final signature. For Over-Seq perturbed single cells, 
gene expression signature was generated by normalizing to negative controls: for raw expression 
matrix described in 6.2.6, first do column-wise rank transformation within the control cells, 
followed by extracting row-wise median and mad values, then do column-wise rank 
transformation within the perturbed cells, and use (rank-median)/mad as final signature. 
6.2.8 Data and software availability 
The expression data of primary single cells reported in this study has been deposited in GEO 
under the accession number GSE98887. The expression data, as well as Over-Seq barcoding 




6.3.1 Identification of pancreatic islet cells under different biological states 
Single pancreatic islet cells from primary donors were harvested (see Methods), and the 
corresponding expression and metaVIPER-inferred transcriptional regulator activity profiles 
were quantified (see Methods), based on which cells were projected onto on 2D-space with t-
SNE [Maaten & Hinton, 2008]. A shown in Figure 6.1, at expression level, I see high-level of 
donor-specificity which is no longer seen using metaVIPER-inferred transcriptional regulator 




It has been shown that hyperglycaemia induces metabolic stress, including oxidative, 
endoplasmic reticulum (ER) and hypoxic stress, leading to the dedifferentiation of β-cells, 
causing type-II diabetes [Kitamura, 2013]. Therefore I first checked the behavior of metabolic 
stress-related transcriptional regulators, including hypoxia stress-related HIF1A [Semenza, 1998], 
oxidative stress-related NFKB1, HSF1, TP53, PI3K, AKT and JNK [Finkel & Holbrook, 2000], 
Figure 6.1 metaVIPER analysis reduces donor-specificity. Profiled single cells were 
projected onto on 2D-space with t-SNE [Maaten & Hinton, 2008] based on (A) expression 
quantified using log2(tpm+1) and (B) metaVIPER-inferred activity. Compared to 
expression, donor-specificity was no longer seen by using metaVIPER analysis. 
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ER stress-related and further autophagy/apoptosis causing ATF4, ATF6, XBP1 and JNK [Xu, 
2005; Maiuri, 2007]. Results showed a clear cell population under metabolic stress state, marked 




Besides metabolic status, I also checked the behavior of cell identity-related transcriptional 
regulators and marker genes, including activity α/β-cell-specific transcriptional regulator IRX2 
and MAFA, as well as expression of α/β-cell-specific markers insulin (INS) and glucagon (GCG) 
[Dorrell, 2011]. Results showed cell identity (majorly α/β-cell lineage) as independent dimension 
Figure 6.2 metaVIPER-inferred activity of metabolic stress-related transcriptional 
regulators. These regulators include hypoxia stress-related HIF1A [Semenza, 1998], 
oxidative stress-related NFKB1, HSF1, TP53, PI3K, AKT and JNK [Finkel & Holbrook, 
2000], ER stress-related and further autophagy/apoptosis causing ATF4, ATF6, XBP1 and 
JNK [Xu, 2005; Maiuri, 2007]. Specifically, due to the negative feedback regulation of 
HIF1A [Ke, 2006], the corresponding activity is reversed. 
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besides cell metabolic status. I also discovered a small population of pancreatic exocrine cells, 





I then checked the behavior of de-differentiation-related transcriptional regulators, including 
positive regulator FOXO1 and negative regulator HES1 (which represses expression of de-
differentiation marker NGN3), as well as stemness-related transcriptional regulators NANOG, 
MYCL and POU5F1 [Talchai, 2012; Kitamura, 2013]. Results showed de-differentiation-related 
transcriptional regulators function among cells under metabolic stress. Specifically, stemness-
Figure 6.3 metaVIPER-inferred activity and expression of pancreatic cell lineage 
markers. These markers include α/β-cell-specific transcriptional regulator IRX2 and MAFA, 
expression markers insulin (INS) and glucagon (GCG) [Dorrell, 2011], as well as pancreatic 
exocrine cell-specific expression markers CELA2A [Kawashima, 1987] 
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related transcriptional regulators were selectively activated in between strong α/β-cell states 
(Figure 6.4). Taking together, these results suggested metabolic stress triggers the function of de-
differentiation-related transcriptional regulators, pushing cells to a more stem-like (de-




6.3.2 Construction of α/β-cell-transition pseudo-lineage, and identification of putative de-
differentiation master regulators 
I further used a principle curve [Hastie & Stuetzle, 1989] to describe the α/β-cell-transition 
pseudo-lineage among the metabolically stressed cells (Figure 6.4A). Alongside the lineage, cells 
Figure 6.3 metaVIPER-inferred activity of de-differentiation/stemness-related 
transcriptional regulators. These regulators include positive/negative de-differentiation 
regulator FOXO1/HES1, and stemness-related transcriptional regulators NANOG, MYCL and 
POU5F1 [Talchai, 2012; Kitamura, 2013]. Specifically, due to the negative feedback 
regulation of HES1 [Hirata, 2002], the corresponding activity is reversed. 
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gradually losing α/β-cell identify, as well as gaining stemness feature (Figure 6.4B, shaded area). 
Noticeably, the shaded stage was majorly composed of cells from diabetic donors, indicating it to 
be the de-differentiated (stem-like) stage. I further identified putative de-differentiation master 
regulators that were activated in this stage (Figure 6.5). 
 
 
Figure 6.4 α/β-cell-transition pseudo-lineage among metabolically stressed cells. (A)  
Principle curve [Hastie & Stuetzle, 1989] representation of the pseudo-lineage. (B) 
Activity/expression of lineage markers, stemness-score, as well as normal/diabetic cell 




6.3.3 Functional validation of putative de-differentiation master regulators 
Dr. Son and I used Over-Seq to test whether putative de-differentiation master regulators can 
reprogram health β-cells (see Methods for details of β-cell enrichment experiment) to de-
differentiated cells, or even α-cells (see Methods). I first quantified Over-Seq barcode, to assign 
perturbation identities of individual cells (see Methods, Figure 6.6).  I then quantified gene 
expression profiles of the perturbed cells (specifically, cells with only 1 detected barcode), and 
further performed transcriptional regulator activity inference (see Methods). 




I projected the perturbed cells onto 2D-space with t-SNE [Maaten & Hinton, 2008] according to 
their expression profiles, and then visualized Over-Seq identity, as well as expression and 
metaVIPER-inferred activity of β/α-cell lineage markers. Specifically I showed health β-cells 
with AFF3 overexpression (Figure 6.7). Results showed cells with AFF3 overexpression formed 
a tight cluster, with losing β-cell identity (decreased INS expression and MAFA activity) and 
gaining α-cell identity (increased GCG expression and IRX2 activity), indicating successful α-
cell to β-cell reprogramming by overexpress AFF3. 
Figure 6.6 Summary of Over-Seq experiment. (A) Distribution of number of barcodes 




Figure 6.7 AFF3-induced α-cell identity among health β-cells. Perturbed cells were 
projected onto 2D-space with t-SNE [Maaten & Hinton, 2008] according to their expression 
profiles. (A) Cells with AFF3 Over-Seq barcode. (B) Negative control cells. (C, D) 
Expression and metaVIPER-inferred activity of AFF3. (E-H) Expression and metaVIPER-






Developing Novel Therapeutics Targeting Cell-
State Regulators of Breast Cancer Stem Cells
	 93	
7.1 Introduction 
Breast cancer stem cells (BCSCs) are originally considered as tumorgenic breast cancer cells: as 
few as 100 BCSCs are able to form tumors in mice, whereas tens of thousands of non-BCSCs 
failed to form tumors. Also, BCSCs could be serially passaged, by generating new tumors 
containing both BCSCs and non-BCSCs [Al-Hajj, 2003]. Later studies associated BCSCs with 
drug resistance, tumor relapse [Dean, 2005], as well as tumor metastasis [Aktas, 2009]. 
Therefore elucidating the molecular regulatory mechinary of BCSCs, and further developing 
corresponding novel targeted therapeutics would greatly help the treatment of breast cancer. 
Previous studies [Alvarez, 2016; Aubry, 2015; Bisikirska, 2016; Brichta, 2015; Carro, 2010; 
Chen, 2014; Chudnowski, 2014; Ding, 2018a; Della Gatta, 2012; Ikiz, 2015; Kushwaha, 2015; 
Lefebvre, 2010; Repunte-Canonigo, 2015; Rodriguez-Barrueco, 2015; Talos, 2017] have shown 
that molecular regulatory mechinary of biological states could be represented by activity of 
transcriptional regulators, which could be predicted by metaVIPER or its precursor MRA 
(Master Regulator Analysis) from transcriptomic profiles. Further, abbarant biological states, e.g. 
tumor-related states, could be treated using drugs identified by OncoTreat analysis [Mitrofanova, 
2015], which identifies drugs that can reverse abbarant transcriptional regulator activity signature. 
However, BCSCs only constitute less then 1% of total cells among breast tumors, which masks 
them really challenging to study using conventional bulk tumor level methodologies. Therefore, 
by combining recently developed  single cell RNA-Seq (scRNA-Seq) technology [Kolodziejczyk, 
2015] with the above-mentioned metaVIPER algorithm, I identified putative BCSC population, 
as well as corresponding master regulators. I further applied OncoTreat analysis to each of the 
identified putative BCSCs, and identified potential targeted therapeutics. 
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7.2 Methods 
7.2.1 Sample collection 
In total Dr. Worley collected 5 primary samples from Columbia University Medical Center, see 
Table 7.1 for detail. Dr. Worley also profiled 1 mouse PDX model from Memorial Sloan 
Kettering Cancer Center, following IACUC guidelines. 
Table 7.1 Primary sample information 
ID Diagnosis Size, Grade, Stage ER PR HER2 Ki67 
FF Carcinoma, Invasive, Ductal – NOS 
Poorly Differentiated (Grade 3), Total 
score 9 (Tubule Score 3, Nuclear Grade 
Score 3, Mitotic Score 3) 
pT1c: Tumor more than 10 
mm but not more than 20 







HD Carcinoma, Invasive with mixed ductal 
and lobular features 
Moderately Differentiated (Grade 2), 
Total score 7 (Tubule Score 3, Nuclear 
Grade Score 2, Mitotic Score 2) 
Ductal carcinoma in situ, nuclear grade 
2, widespread 30-40 % 
Intraductal cribriform subtype 
Necrosis is present within the intraductal 
carcinoma 







Neg. IHC 0 20% 
IF Invasive ductal carcinoma, well-
differentiated with focal tubular 
features, modified Scarff- Bloom- 
Richardson grade 1 (2 + 2 + 1), 
pT1c: Tumor more than 10 
mm but not more than 20 






Neg. IHC 1+, 
SISH negative 
10% 






Neg.IHC 0 2% 
JC Invasive ductal carcinoma, poorly 
differentiated, modified Scarff-Bloom-
Richardson score 8-9 (3, 2-3, 3). 
pT2: Tumor more than 20 
mm but not more than 50 
mm in greatest dimension. 
Two foci  (M=2) of 
invasion are present, the 
larger is pT2. 
pN0(sn) 
Neg. 0 Neg.0 Neg.IHC0 35% 
 
7.2.2 Tumor dissociation 
After being picked up from pathology, tumor tissue was manually separated from necrotic tissue. 
Next, the samples were dissociated using a Miltenyi gentleMACS Octo dissociator, according to 
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the manufacturer’s instructions. To maintain transcriptome integrity, the samples were processed 
quickly and kept on ice as much as possible. Generally, the time from retrieval to lysis was 
approximately 4 hours, with less than 90 minutes above 0°C. 
7.2.3 Enrichment of putative BCSCs 
After dissociation, the single-cell suspension was filtered, treated with ACK buffer to lyse red 
blood cells, and then stained and sorted for CD49f(high), EpCAM(positive), DAPI(negative), 
and lineage(negative) using a BD Influx flow sorter. This FACS protocol removed 
approximately 95-99% of cells, with the remainder being enriched for BCSCs. 
7.2.4 Single cell RNA sequencing 
Single cells obtained from primary patients were processed following standard scPLATE-Seq 
protocol (see Part I for details). Single cells obtained from mouse PDXs were processed 
following standard 10x Genomics Chromium protocol. 
7.2.5 scRNA-Seq gene expression analysis 
Single cell profiled using scPLATE-Seq were analyzed following same pipeline described in 
section 1.2.2. Single cells profiled using 10x Genomics Chromium were analyzed using standard 
10x Genomics Cell Ranger pipeline. 
7.2.6 Regulatory networks and protein activity profiles 
Protein and microRNA activity profiles were inferred from expression matrix by integrating the 
core TCGA regulatory networks [Giorgi, 2017] and CUPID microRNA regulatory networks 
[Sumazin , 2011] with metaVIPER [Alvarez, 2016; Ding, 2018], respectively. 
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7.2.7 OncoTreat analysis 
As described in [Mitrofanova, 2015], OncoTreat analysis identifies drugs that can reverse the 
tumor-specific transcriptional regulator activity signature. So that, in this specific study, I either 
kill putative BCSCs or push them to more differentiated thereby treatable states. To archive this, 
I first identified the best matching cell line for each profiled single cell using gene set enrichment 
analysis (GSEA) [Subramanian, 2005]. I used each single cell’s top 25 most activated/suppressed 
transcriptional regulators as gene set, and the transcriptional regulator activity profile for each 
cell line (see section 7.2.8, available as part of OncoTreat pipeline) as GSEA signature. Cell line 
that gives highest normalized enrichment score (nES) will be considered as best-matching one 
for each profiled single cells. I further identified best matching cell line for putative BCSCs, by 
checking the distribution of cell lines’ nESs alongside the constructed BCSC-differentiated 
breast cancer cell pseudo-lineage. I then identified drugs that can reverse the transcriptional 
regulator activity signature of the BCSCs using GSEA. I used each single cell’s top 25 most 
activated/suppressed transcriptional regulators as gene set, and the transcriptional regulator 
activity profile for each drug perturbation of the best-matching cell line (see section 7.2.8, 
available as part of OncoTreat pipeline) as GSEA signature. Drug perturbation that gives lowest 
normalized nES will be considered as best candidate for treating putative BCSCs (see Figure 7.1 
for schematic workflow of OncoTreat). 
7.2.8 Data and software availability 
The expression data of primary single cells reported in this study has been deposited in GEO 
under the accession number GSE108540. The expression data of mouse PDXs single cells 
reported in this study is available upon request to the authors. The transcriptional regulator 
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activity profiles for native cell lines, and cell lines with drug perturbations used in OncoTreat 




7.3.1 Construction of BCSC-differentiated breast cancer cell pseudo-lineage 
Single breast cancer stem cells from primary patients were harvested (see Methods), and the 
corresponding expression and metaVIPER-inferred transcriptional regulator activity profiles 
were quantified (see Methods), based on which cells were projected onto on 2D-space with t-
SNE [Maaten & Hinton, 2008]. A shown in Figure 7.2, at expression level, I see high-level of 
Figure 7.1 Schematic workflow of OncoTreat. 
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patient-specificity (cells clustered according to their corresponding patient IDs, e.g. the upper-
left cluster is composed of jc cells), as well as slight batch effect (among patient-specific cell 
clusters, e.g. upper-left jc cluster, cells profiled within the same scPLATE-Seq plate, e.g. jc1, 
tend to co-segregate). These were no longer seen using metaVIPER-inferred transcriptional 
regulator activity, allowing us to have fine-tuned annotation of cells. With metaVIPER-analysis, 
cells from different patients/batches mixed together and formed a “microphone” shape. As 
shown in Figure 7.3, metaVIPER-inferred activity of well-established BCSC-specific 
transcriptional regulators, including WNT1, NITCH1, SHH and BMI1 [Al-Hajj & Clarke, 2004] 
indicated putative BCSCs were enriched in the head of the “microphone”, while differentiated 
breast cancer cells were enriched in the handle of the “microphone”. Specifically, I checked the 
activity of microRNAs 200c (miR-200c, see Methods, Figure 7.4). Since not poly-adenylated, 
the abundance of microRNAs is not detectable using regular scRNA-Seq. However given proper 
regulatory networks, the activity of microRNAs can be correctly inferred. In this case, the 
activity of miR-200c goes opposite with BCSC-specific transcriptional regulators BMI1, in 
consistence with the fact that miR-200c was considered as suppressor of BMI1 [Shimono, 2009]. 
Taking together, metaVIPER analysis revealed a BCSC-differentiated breast cancer cell pseudo-
lineage, which was further described by a principle curve [Hastie & Stuetzle, 1989] on the t-SNE 






Figure 7.2 metaVIPER analysis reduces patient-specificity and batch effect, which 
facilitated the construction of BCSC-differentiated breast cancer cell pseudo-lineage. 
Profiled single cells were projected onto on 2D-space with t-SNE [Maaten & Hinton, 2008] 
based on (A) expression quantified using log2(tpm+1) and (B) metaVIPER-inferred activity. 
Compared to expression, patient-specificity and batch effect were no longer seen by using 
metaVIPER analysis, which further revealed a BCSC-differentiated breast cancer cell 






Figure 7.3 metaVIPER-inferred activity of well-established BCSC-specific 
transcriptional regulators (non-microRNAs) among primary cells. Blue-to-red color 
gradient indicated low-to-high metaVIPER-inferred activity. 
Figure 7.4 metaVIPER-inferred activity of miR-200c among primary cells. Blue-to-red 
color gradient indicated low-to-high metaVIPER-inferred activity. 
	 101	
7.3.2 Identification of novel BCSC-associated transcriptional regulators 
I further identified BCSC-associated transcriptional regulators (Figure 7.5), including 
microRNAs (Figure 7.6), according to the enrichment of regulator-specific highly-activated cells 




Figure 7.5 Novel BCSC-associated transcriptional regulators (non-microRNAs). Blue-




7.3.3 BT20 as representative cell line for putative BCSCs 
To identify drugs using OncoTreat that can reverse the putative BCSC-specific transcriptional 
regulator activity signature so that I either kill or push them to more differentiated thereby 
treatable states, I first need to identify cell lines that best represent putative BCSCs, by 
measuring the similarity between single cells and cell lines using GSEA normalized enrichment 
score (nES).	For each profiled single cell, I used top 25 most activated/suppressed transcriptional 
regulators as gene set, and the transcriptional regulator activity profile for each cell line as 
signature for gene set enrichment analysis (GSEA) [Subramanian, 2005], see Methods for detail. 
Result showed breast cancer cell line BT20 [Lasfargues & Ozzello, 1958] to be the best match 
with previously identified putative BCSCs (Figure 7.7). 
Figure 7.6 Novel BCSC-associated microRNAs. Blue-to-red color gradient indicated low-




7.3.4 Crizotinib, Etopiside and Gemcitabine as best candidate for treating putative BCSCs 
I then performed OncoTreat analysis (see Methods) on putative BCSCs against drug perturbation 
(different drugs, IC20 and IC50 for each drug, 6h and 24h treatment time) profiles of BT20 cell 
line, which was used as substitution of drug perturbation profiles of putative BCSCs, because 
dealing with primary cells is usually hard. In theory, if the reversion of putative BCSC-specific 
transcriptional regulator activity signature can be made by certain perturbation, the 
transcriptional regulator activity profile for that specific perturbation should anti-correlate with 
the transcriptional regulator activity profile of BT20 cell line. Based on this, the signature 
reversion was quantified by dis-similarity between profiled single cells and BT20 perturbations 
using GSEA nES. For each profiled single cell, I used the top 25 most activated/suppressed 
transcriptional regulators as gene set, and the transcriptional regulator activity profile for each 
Figure 7.7 BT20 as representative cell line for putative BCSCs obtained from primary 
samples. Blue-to-red color gradient indicated low-to-high GSEA nES. 
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BT20 perturbation as GSEA signature. Result showed regardless of treating concentration and 
time, Crizotinib, Etopiside and Gemcitabine consistently reversed BCSC-specific transcriptional 





Figure 7.8 Crizotinib, Etopiside and Gemcitabine as best candidate for treating 
putative BCSCs obtained from primary samples. Blue-to-red color gradient indicated 
low-to-high GSEA nES. 
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7.3.5 Identification and treatment of putative BCSCs among mouse PDX models 
Similar with primary patient samples, single breast cancer stem cells from mouse PDX models 
were harvested and analyzed. As shown in Figure 7.9, metaVIPER-inferred activity of WNT1, 
NITCH1, SHH and miR-200c indicated putative BCSCs were recapitulated, further suggested 
mouse PDXs as proper models for studying the regulatory mechanism and therapeutic strategies 
of putative BCSCs. Similarly, BT20 was shown to be representative cell line for putative BCSCs 
(Figure 7.10), and Crizotinib, Etopiside, Gemcitabine were shown to be best candidate for 
treating putative BCSCs (Figure 7.11) among mouse PDX models. 
 
 
Figure 7.9 metaVIPER-inferred activity of well-established BCSC-specific 
transcriptional regulators among single cells obtained from mouse PDX models. Blue-





Figure 7.10 BT20 as representative cell line for putative BCSCs obtained from mouse 
PDX models. Blue-to-red color gradient indicated low-to-high GSEA nES. 
Figure 7.11 Crizotinib, Etopiside and Gemcitabine as best candidate for treating 
putative BCSCs obtained from mouse PDX models. Blue-to-red color gradient indicated 








In this thesis I describe the development of two analytical tools for better understanding 
biological states of single cells, including metaVIPER and iterClust; the development of single 
cell RNA-Seq platform, scPLATE-Seq. Combining these, I answered three specific biological 
questions, including 1) understanding the inter- and intra-tumor molecular subclasses of human 
glioblastoma, 2) elucidating regulators of β-cell de-differentiation in type-2 diabetes and 3) 
developing novel therapeutics targeting cell-state regulators of breast cancer stem cells. 
Currently, metaVIPER and iterClust have been published. scPLATE-Seq and the glioblastoma 
studies are under submission. Discoveries in the type-2 diabetes and breast cancer stem cell 
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A.1 Materials and equipment:   
A.1.1 Lysis Buffer 
• SUPERaseIn RNase inhibitor, 20U/µl (Ambion, #AM2696) 
• Triton X-100, 10% (Sigma-Aldrich, #93443) 
• dNTP set, 100mM each (Thermo Scientific, #R0181) 
• HyClone water (GE Healthcare, #SH30538.01) 
• Oligo(dT) mRNA capture primers, AAGCAGTGGTATCAACGCAGAGTAC[8 bp 
barcode]N(8)T(29)V, (IDT).  
• Template switch oligo (TSO), AAGCAGTGGTATCAACGCAGAGTGAATrGrGrG 
(IDT) 
A.1.2 RT Mix 
• Betaine, ultrapure (Alpha Aesar, #J77507) 
• ProtoScript II reverse transcriptase (NEB, #M0368X) 
• MgCl2, 2M, cell culture grade (Fisher Scientific, #BP9741-10X5) 
• Dithiothreitol (DTT), ultrapure (Invitrogen, #15508013) 
• HyClone water (GE Healthcare, #SH30538.01) 
 
	 121	
A.1.3 Exo I digestion Mix 
• Exonuclease I, 20U/µl (Thermo Scientific, #EN0582) 
• HyClone water (GE Healthcare, #SH30538.01) 
A.1.4 Pooling and Concentration 
• Dynabeads MyOne Silane (ThermoFisher, #37002D) 
• Buffer RLT Plus (Qiagen, #1053393)  
• Ethanol, 200 proof (Sigma-Aldrich, #E7023) 
A.1.5 Pre-amplification PCR Mix 
• KAPA HiFi HotStart ReadyMix, 2X (Kapa Biosystems, #KK2612) 
• SMART PCR primer, AAGCAGTGGTATCAACGCAGAGT 
A.1.6 Nextera amplification 




• Eppendorf  twin.tec PCR Plate 96, semi-skirted (Eppendorf, #951020303) 
• Microseal 'F' PCR Plate Seal, foil, (Biorad, #MSF1001) 
• Speedball soft rubber brayer, 3.5’’ (Speedball, #004174) 
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• Eppendorf DNA LoBind microcentrifuge tubes, 1.5ml and 2ml (Eppendorf, #022431021 
and #022431048) 
• Agilent 2100 Bioanalyzer  
• Agilent high-sensitivity DNA kit (Agilent, #5067-4626) 
• Qubit 2.0 fluorometer (ThermoFisher) 
• Qubit dsDNA high-sensitivity kit (ThermoFisher, #Q32854) 
• Magnetic separators for 1.5ml and 15ml tubes (Invitrogen, #12321D and #12301D, or 
equivalent) 
• Vortex mixer (Fisher #02-215-414, or equivalent) 
• Multi-channel Pipettes (Integra Viaflow II, #4011, or similar) 
• Eppendorf cold blocks (#022510541) 
A.2 Procedure 
Steps 1-6: Lysis plate preparation 
1. Critical: At all steps, be meticulous to avoid contamination. Work in a PCR hood 
whenever possible. Wear disposable Tyvek sleeves or coat in the hood prior to 
amplification. All reagents must be free of DNA, RNA, and nucleases. Single-cell library 
quality can be significantly affected by small changes in reagents (concentration, age, or 
manufacturer). Avoid multiple freeze-thaw cycles (aliquot reagents). Prior to beginning, 
clean all surfaces to remove nucleic acid and nuclease contamination.  
2. Prepare lysis buffer mix. For each sample prepare 6µl of lysis mix: 5.33µl Hyclone H2O, 
0.15µl of 10% Triton X-100, 0.38µl of SUPERaseIN, and 0.15µl of 100mM dNTP mix. 
Make at least 1.2X the volume required. 
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• In the lysis and binding steps, the concentration of Triton X-100, SUPERaseIN, 
and dNTP mix will be 0.2%, 1U/µl, and 2mM, respectively. 
3. Load 6µl of lysis mix into each well of a 96-well plate. (This, and subsequent steps, 
should be carried out with multi-channel pipettes or using a liquid handling robot.)  
4. Add 1.5µl of 10µM mRNA capture primers into each well. Mix thoroughly.  
5. Seal plates. If plates will be stored frozen, meticulously seal using Biorad Microseal F 
foil or -80C safe film.  
6. Centrifuge plate briefly at 4C to collect liquid. Plates can be kept at 4C for same-day use 
or stored at -80C for up to 1 month.  
Steps 7-9: Loading samples into lysis plates 
7. Centrifuge plate briefly to defrost plates and collect liquid. Put plates in Eppendorf cold 
blocks. 
8. Load samples into plates. NOTE: If using FACS to load plates: 1) carefully align sorter 
using same model plates. One method of alignment is to sort a visible number of droplets 
onto a plate sealed with optical film. Align sorter so the droplet is dead center at all four 
corner wells. 2) observe stream stability. Large or irregular cells can destabilize the 
stream and lead to empty wells.  
9. Thoroughly seal plates with -80C safe foil (or optical seal) and spin down for 2min at full 
speed, 4C. NOTE: plates can be stored at -80C for up to two weeks.  
Steps 10-15: Reverse transcription 
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10. Prepare reverse transcription (RT) mix. For each sample, prepare 7.5µl of RT mix. 
Combine 3 µl 5X RT buffer, 3 µl of 5M betaine, 0.45µl of 200mM MgCl2, 0.075 µl of 
1M DTT, 0.2 µl of 200U/µl ProtoScript II reverse transcriptase, 0.2 µl of 20U/µl 
SUPERaseIN, 0.15µl of 100µM template switch oligo, and 0.43µl of Hyclone water. 
Make at least 1.2X the volume required. 
• In the final 15µl reaction, the concentrations will be: 1M betaine, 1X RT buffer, 
6mM MgCl2, 5mM DTT, 40U RT enzyme, 7.5U SUPERaseIN, and 1µM 
template switch oligo. 
• NOTE: DTT should be fresh or from frozen aliquot that has not been repeatedly 
freeze-thawed. 1M DTT may precipitate in the freezer, but can be resuspended by 
warming for a few minutes at room temperature or 37C, and then vortexing. The 
template switch oligo should be aliquoted and stored at -80C.  
11. Centrifuge at room temperature, full speed, for 2min.  
12. Run primer anneal program on thermal cycler. 72C (3min)à4C (infinite) 
13. Add RT mix to plate and mix thoroughly. As much as possible, keep mix and plate near 
0C throughout.  
14. Apply seal and quickly spin plate at 4C.  
15. Run RT program. 
• Stage 1: 42C (90min) 
• Stage 2: 10 cycles of: 50C (2min)à42C (2min) 
• Stage 3: 75C (10min)à4C (infinite) 
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Steps 16-18: Exonuclease I cleavage 
16. Centrifuge plate briefly at 4C.  
17. Dilute Exonuclease I to 7.5U/µl in 1X Exo I buffer and add 2µl (15U) to each sample. 
Mix thoroughly.  
18. Run Exo I program on thermal cycler. 37C (30min)à80C (15min)à4C (infinite).  
Steps 19-32: Pooling and cleanup 
19. Centrifuge plate briefly at 4C. 
20. Pool samples in 15ml polypropylene tube.  
21. Clean up pooled samples with silane beads. In 15ml tube, combine sample (e.g., 1400µl) 
with cleanup mix: 
• 3.5 volumes RLT Plus (e.g., 4,900µl) 
• EtOH to 33% final (e.g., 2,771µl) 
• 3µl silane beads for each 300µl solution (e.g., 91µl).  
22. Vortex to mix. Incubate at room temperature for 20min on rotator.  
23. Collect beads on magnetic stand. Remove most supernatant, but leave ~1ml remaining.  
24. Resuspend beads in remaining 1ml supernatant and transfer to 1.5ml tube.  
25. Collect beads on magnetic stand. Remove supernatant.  
26. Wash beads 2X with 500µl 80% EtOH. 
27. Remove remaining EtOH with p10 tip and dry pellet in hood. Do not over dry.  
28. Elute in 100µl Hyclone H2O. Vortex tube for 1min, and then flick or very briefly pulse 
the sample in a microcentrifuge. Incubate 1min at room temperature and then collect 
beads on magnet and remove the supernatant into two PCR tubes (47.5µl each).   
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29. Add 50µl 2X Kapa HiFi Hotstart and 2.5µl 10µM SMART PCR primer into each tube. 
Mix and quickly spin down PCR mix. 
30. Run SMART PCR program on thermal cycler. NOTE: The number of amplification 
cycles required can vary from 13-20, depending on cell type and state. Because over 
amplification can lead to both PCR bias and recombination, it is important to use the least 
amount of amplification that yields a sufficient library. To determine this, run the first 
plate for either 14 cycles (large cell lines) or 18 cycles (small primary cells); clean up, 
and determine concentration using Qubit DNA HS. Adjust the number of cycles for the 
remaining plates.  
• Stage 1: 98C (3min) 
• Stage 2: 98C (20seconds)à67C (15seconds)à72C (5min) 
• Stage 3: 72C (5min)à4C (infinite) 
31. Pool the two PCR reactions into a 1.5ml tube. Measure the total volume (slightly less 
than 200µl).  
32. Clean up using Ampure XP with 0.7:1 ratio. Elute in 22µl Hylcone water. Remove 20µl 
to a new tube. Take care not to transfer any beads, which can ruin the Bioanlyzer run.  
Steps 32-35: Library quantification and sequencing 
33. Determine library concentration using 3µl of sample for Qubit HS analysis.  
• NOTE: in some cases libraries can successfully be sequenced from low 
concentration samples (e.g., less than 0.07ng/µl), but such libraries may not be 
visible in the Bioanalyzer, and the Nextera tagmentation reaction will have to be 
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loaded blind. It is generally preferable to optimize the preamplification PCR to 
have a Qubit concentration of 0.1-0.4ng/µl. Do not over amplify.  
• NOTE: low concentration samples can be concentrated using a Speedvac. 
However, do not dry the sample—reduce the volume to ~10µl.  
34. Determine average library size using Bioanalyzer DNA HS. Average fragment size 
should be 1,600-1,900bp. 
• NOTE: When running low concentration samples, the Bioanalyzer is very 
sensitive to contaminants, including beads, reagents, and air bubbles. Take extra 
care and include a blank well.  
• NOTE: Average fragment sizes below ~1,600bp often contain degradation. If the 
protocol has been followed closely, it is likely that such contamination was 
present in the cells prior to lysis. In some cases, such as tumor samples, such 
degradation may be unavoidable. Libraries with average fragment sizes as low as 
~1,100bp have been successfully sequenced, but data quality is affected.  
35. Perform Nextera XT DNA Library Prep with the following modifications: 
• Load 0.5ng of sample into the tagmentation reaction instead of the stated 1ng.  
• Use 5µl of Index 1 (i7) adapter/primer and 5µl of 5µM Nextera PCR primer 
• Following tagmentation and amplification, cleanup with 0.6X:1 ratio Ampure XP, 
followed by an additional cleanup using 1:1 ratio Ampure XP. Elute in 22µl RSB. 
• Run sample on Bioanalyzer DNA HS. Average fragment size should be between 
300bp and 600bp. No primer dimers should be present. 
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Appendix B 
Data and Software Availability for scPLATE-Seq 
All described expression profiles have been deposited at the Gene Expression Omnibus (GEO) 
under accession number GSE104493. 




Data and Software Availability for metaVIPER 
scRNA-Seq data for the mouse glioblastoma model described have been deposited at the Gene 
Expression Omnibus (GEO) under accession number GSE95157. 
R-package aracne.networks is available on Bioconductor 
(https://bioconductor.org/packages/release/data/experiment/html/aracne.networks.html). 
Tirosh human cutaneous melanoma (SKCM) dataset was downloaded from GEO with accession 
number GSE72056. 
SKCM, B and T lymphocyte interactomes: https://figshare.com/s/565815d2e44c7e3b2b36 
Brain tumor interactomes: https://figshare.com/s/97fb0a95e9fc708b8c96 
TCGA expression and somatic mutation profile: http://cancergenome.nih.gov/. 
REMBRANDT data set: https://gdoc.georgetown.edu/gdoc/. 
COSMIC somatic mutation profile: http://cancer.sanger.ac.uk/cosmic. 
Filtered PBMC scRNA-Seq expression profiles generated using 10x Genomics V2 chemistry: 
https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.0.1/pbmc4k 
Filtered PBMC scRNA-Seq expression profiles generated using 10x Genomics V1 chemistry: 
https://support.10xgenomics.com/single-cell-gene-expression/datasets/1.1.0/pbmc3k 
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Data and Software Availability for iterClust 
Filtered Chromium 10X Genomics public PBMC scRNA-Seq profiles were downloaded from 
https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.1.0/pbmc4k and 
https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.1.0/pbmc8k. 
Tirosh human cutaneous melanoma (SKCM) dataset was downloaded from GEO with accession 
number GSE72056. 
Clustering analysis benchmarking datasets were downloaded from 
https://cs.joensuu.fi/sipu/datasets/. 
iterClust R package can be found on Bioconductor 
(https://bioconductor.org/packages/release/bioc/html/iterClust.html), as well as GitHub 
(https://github.com/hd2326/iterClust). 
